[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 355
1. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV: Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol; 2009;9:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia.
  • We assessed the prognostic significance of tumour infiltrating lymphocytes (TIL) in intestinal-type gastric cardiac cancer.
  • CONCLUSION: Our results suggest that inflammatory processes within the tumour stroma of gastric intestinal-type adenocarcinomas located at the gastric cardia may affect outcome in two ways.
  • Thus, inhibition of Treg may not be a feasible treatment option in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology. Stromal Cells / pathology. T-Lymphocytes, Regulatory / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):685-94 [18834412.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):4079-83 [14666722.001]
  • [Cites] BMJ. 2004 May 1;328(7447):1073 [15117797.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • [Cites] Cancer Detect Prev. 1995;19(2):156-64 [7750103.001]
  • [Cites] J Surg Res. 2005 Mar;124(1):151-7 [15734494.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):186-92 [19064967.001]
  • [Cites] Nat Rev Immunol. 2009 Feb;9(2):83-9 [19114986.001]
  • [Cites] Annu Rev Immunol. 2000;18:423-49 [10837065.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Cancer Immunol Immunother. 2006 Sep;55(9):1064-71 [16328385.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3355-60 [16740757.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Clin Immunol. 2006 Dec;121(3):358-68 [16934529.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):60-9 [17200707.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] Jpn J Clin Oncol. 2007 May;37(5):365-9 [17578895.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1596-602 [17459024.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8 [18058571.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):148-53 [18087278.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Cell Immunol. 2007 Nov-Dec;250(1-2):1-13 [18313653.001]
  • [Cites] Integr Cancer Ther. 2008 Jun;7(2):90-5 [18550889.001]
  • [Cites] EMBO J. 2008 Jun 18;27(12):1671-81 [18511911.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • (PMID = 19732435.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Other-IDs] NLM/ PMC2749861
  •  go-up   go-down


2. Wang GQ, Jiao GG, Song JX, Fang WH, Lü N, Lin DM, Xie YQ, Zhang JH, Wei WQ: [Diagnosis and long-term results of surgical resection of early cardiac adenocarcinoma]. Zhonghua Wai Ke Za Zhi; 2008 Jul 15;46(14):1045-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and long-term results of surgical resection of early cardiac adenocarcinoma].
  • OBJECTIVE: To summarize therapeutic experience and the long-term results of early cardiac adenocarcinoma with surgical resection.
  • METHODS: Ninety cases were diagnosed with early cardiac adenocarcinoma during endoscopic screening in high incidence rate area of esophageal cancer from 1972 to 1997.
  • Cardiectomy included partial stomach and esophagus was performed through left thoracotomy in all patients.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094526.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


3. Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, Palli D, Saieva C, Krogh V, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Sanchez MJ, Larrañaga N, Barricarte A, Chirlaque MD, Quirós JR, Key TJ, Allen N, Lund E, Carneiro F, Linseisen J, Nagel G, Overvad K, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Ocké MO, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Fenger C, Stenling R, Ferrari P, Jenab M, Norat T, Riboli E, Gonzalez CA: Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis; 2006 Jul;27(7):1497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study.
  • The risk of gastric cancer (GC) associated with dietary intake of nitrosodimethylamine (NDMA) and endogenous formation of nitroso compounds (NOCs) was investigated in the European Prospective Investigation into Cancer and Nutrition (EPIC).
  • ENOC was significantly associated with non-cardia cancer risk (HR, 1.42; 95% CI, 1.14-1.78 for an increase of 40 microg/day) but not with cardia cancer (HR, 0.96; 95% CI, 0.69-1.33).
  • ENOC formation may account for our previously reported association between red and processed meat consumption and gastric cancer risk.
  • [MeSH-major] Adenocarcinoma / epidemiology. Diet. Nitrosamines / metabolism. Nitrosamines / pharmacology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. N-NITROSODIMETHYLAMINE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571648.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrosamines; E1UOL152H7 / Iron; M43H21IO8R / Dimethylnitrosamine; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


Advertisement
4. Lu CC, De-Chuan C, Lee HS, Chu HC: Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases. Am J Surg; 2010 Apr;199(4):e42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases.
  • The authors report a rare case of hepatoid adenocarcinoma of the stomach, presenting initially with spleen and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cardia. Liver Neoplasms / diagnosis. Lymph Nodes / pathology. Splenic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359564.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


5. Kofoed SC, Brandt B, Brenø J, Bardram L, Gustafsen J, Holm J, Jendresen M, Svendsen LB: [Long-term survival after curative resection for oesophageal and cardia cancer]. Ugeskr Laeger; 2010 May 24;172(21):1597-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival after curative resection for oesophageal and cardia cancer].
  • Adenocarcinoma was found in 93% of the patients and squamous cell carcinoma in 7%.
  • Cardia resection was performed in 78%, while 22% underwent gastrectomy.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Cardia. Esophageal Neoplasms / mortality. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20525472.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


6. Moenig SP, Luebke T, Baldus SE, Schroeder W, Bollschweiler E, Schneider PM, Hoelscher AH: Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases. Anticancer Res; 2005 Mar-Apr;25(2B):1349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases.
  • BACKGROUND: The feasibility and diagnostic reliability of sentinel lymph node biopsy of gastric carcinoma are still unclear and controversial.
  • PATIENTS AND METHODS: To assess the applicability of the sentinel node concept to gastric carcinoma, we retrospectively analyzed the location of metastatic lymph nodes in patients with only one or two lymph node metastases.
  • RESULTS: A total of 135 patients, who underwent gastrectomy with D2 lymphadenectomy for primary gastric adenocarcinoma between 1997 and 2001, were enrolled in this study.
  • Skip metastases were only seen in one patient with cardia carcinoma and lymph node involvement of compartment II (left gastric artery).
  • CONCLUSION: In patients with gastric carcinoma, especially in early stage carcinoma, the phenomenon of skip metastasis is infrequent.
  • Therefore, the sentinel node concept may be feasible in gastric cancer.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865090.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Gao SG, Wang LD, Fan ZM, Li JL, He X, Guo RF, Xie DL, He XW, Gao SS, Guo HQ, Wang JK, Feng XS, Ma BG: Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol; 2005 Aug 14;11(30):4634-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China.
  • AIM: To characterize the histochemical type and pattern of intestinal metaplasia (IM) adjacent to gastric cardia adenocarcinoma (GCA) and distal gastric cancer (GC) in Linzhou, Henan Province, China.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094701.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065871; United States / NCI NIH HHS / CA / CA65871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4615402
  •  go-up   go-down


8. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J: Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer; 2006 Jul 3;95(1):118-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
  • Standardised incidence ratios (SIRs) of oesophageal and gastric cancer represented relative risks.
  • Among 138 885 cohort members contributing with 1 075 724 person-years of follow-up, we found a nonsignificantly increased risk of oesophageal adenocarcinoma during the potential tamoxifen exposure period (SIR 1.60, 95% confidence interval (CI) 0.83-3.08), but the risk estimates decreased with increasing latency interval.
  • No increased risk of cardia adenocarcinoma was identified in either period.
  • The risk of non-cardia gastric adenocarcinoma was increased in the potential tamoxifen period (SIR 1.27, 1.03-1.57), and almost doubled (SIR 1.86, 95% CI 1.10-3.14) in the period of longest latency (10-14 years).
  • We concluded that there might be a link between tamoxifen and risk of non-cardia gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Breast Neoplasms / drug therapy. Carcinoma, Squamous Cell / chemically induced. Esophageal Neoplasms / chemically induced. Lung Neoplasms / chemically induced. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1537-43 [11205460.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 [12160084.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):117-20 [2563046.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1007-10 [2667745.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1013-7 [2072407.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):832-4 [8637050.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • (PMID = 16755290.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ PMC2360495
  •  go-up   go-down


9. Kamangar F, Qiao YL, Schiller JT, Dawsey SM, Fears T, Sun XD, Abnet CC, Zhao P, Taylor PR, Mark SD: Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China. Int J Cancer; 2006 Aug 1;119(3):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China.
  • Each year, esophageal and gastric cancers cause more than 900,000 deaths worldwide.
  • We conducted a large prospective study to examine the association between serum antibodies to HPV 16, HPV 18 and HPV 73 and subsequent development of esophageal squamous cell carcinoma (ESCC), gastric cardia adenocarcinoma (GCA), and gastric noncardia adenocarcinoma (GNCA) in a high-risk population for these cancers in Linxian, China.
  • The results of this study do not support a major role for HPV 16, HPV 18 and HPV 73 in the etiology of esophageal and gastric cancers in Linxian, China.
  • [MeSH-major] Antibodies, Viral / blood. Esophageal Neoplasms / etiology. Papillomavirus Infections / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16496409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


10. Jenab M, Riboli E, Ferrari P, Friesen M, Sabate J, Norat T, Slimani N, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Boeing H, Schulz M, Linseisen J, Nagel G, Trichopoulou A, Naska A, Oikonomou E, Berrino F, Panico S, Palli D, Sacerdote C, Tumino R, Peeters PH, Numans ME, Bueno-de-Mesquita HB, Büchner FL, Lund E, Pera G, Chirlaque MD, Sánchez MJ, Arriola L, Barricarte A, Quirós JR, Johansson I, Johansson A, Berglund G, Bingham S, Khaw KT, Allen N, Key T, Carneiro F, Save V, Del Giudice G, Plebani M, Kaaks R, Gonzalez CA: Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer; 2006 Aug 07;95(3):406-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition.
  • Despite declining incidence rates, gastric cancer (GC) is a major cause of death worldwide.
  • The objective of this study was to determine the association of plasma levels of seven common carotenoids, their total plasma concentration, retinol and alpha- and gamma-tocopherol, with the risk of gastric adenocarcinoma in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), a large cohort involving 10 countries.
  • A secondary objective was to determine the association of total sum of carotenoids, retinol and alpha-tocopherol on GCs by anatomical subsite (cardia/noncardia) and histological subtype (diffuse/intestinal).
  • [MeSH-major] Adenocarcinoma / epidemiology. Carotenoids / administration & dosage. Diet. Stomach Neoplasms / epidemiology. Tocopherols / administration & dosage. Vitamin A / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2087-92 [16172214.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):480-4 [7759153.001]
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):133-40 [10861464.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3479S-3485S [15570057.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):145-50 [8603802.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Mar;13(3):233-7 [11293441.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 May;12(5):497-503 [10833091.001]
  • [Cites] Eur J Clin Nutr. 2005 Dec;59(12):1397-408 [16160701.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1997 Jun 20;694(1):71-81 [9234850.001]
  • [Cites] Cancer. 1993 May 15;71(10):2926-33 [8490820.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Clin Chem. 1989 Dec;35(12):2313-6 [2591049.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):737-48 [10679641.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1145-9 [8602179.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):896-901 [2335393.001]
  • [Cites] Cancer Causes Control. 2003 Sep;14(7):645-55 [14575362.001]
  • [Cites] Nutr Cancer. 1999;34(1):56-61 [10453442.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1772-80 [15533906.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7501-4 [2253198.001]
  • [Cites] Am J Clin Nutr. 1983 Oct;38(4):631-9 [6624705.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):638-44 [8194870.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1414-6 [13130117.001]
  • [Cites] Cancer Res. 1983 Jul;43(7):3034-40 [6189589.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] N Engl J Med. 1984 Feb 16;310(7):430-4 [6537988.001]
  • [Cites] Int J Epidemiol. 1997;26 Suppl 1:S6-14 [9126529.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:73-82 [9701005.001]
  • [Cites] Nutr J. 2004 Oct 20;3:19 [15496224.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8 [11106679.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1941s-1943s [8137316.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1424S-1426S [7495242.001]
  • [Cites] Am J Epidemiol. 1994 Mar 1;139(5):466-73 [8154470.001]
  • [Cites] Dig Liver Dis. 2002 Sep;34 Suppl 2:S72-7 [12408446.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):585-90 [10521790.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):195-202 [9103291.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1021-8 [9305701.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):559S-569S [12936950.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):369-74 [2040530.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):811-4 [8896892.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] Am J Epidemiol. 1991 Apr 15;133(8):766-75 [2021143.001]
  • [Cites] Am J Epidemiol. 1995 Nov 1;142(9):955-60 [7572976.001]
  • [Cites] Eur J Clin Nutr. 2005 Dec;59(12):1387-96 [16160702.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1607-12 [11018097.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):71-5 [10334645.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1338-44 [16174855.001]
  • [Cites] Scand J Gastroenterol. 1998 Mar;33(3):294-300 [9548624.001]
  • [Cites] Jpn J Cancer Res. 1995 Oct;86(10):916-23 [7493909.001]
  • [Cites] Cancer Causes Control. 1991 Jul;2(4):227-33 [1873452.001]
  • (PMID = 16832408.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527; United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11103-57-4 / Vitamin A; 1406-66-2 / Tocopherols; 36-88-4 / Carotenoids
  • [Other-IDs] NLM/ PMC2360629
  •  go-up   go-down


11. Lamb PJ, Griffin SM, Burt AD, Lloyd J, Karat D, Hayes N: Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. Br J Surg; 2005 Jan;92(1):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma.
  • BACKGROUND: The aim of this study was to determine the feasibility and accuracy of sentinel lymph node (SLN) biopsy for oesophageal adenocarcinoma.
  • METHODS: Fifty-seven patients with adenocarcinoma of the lower oesophagus (n = 40) or gastric cardia (n = 17) underwent endoscopic peritumoral injection of (99m)Tc-radiolabelled nanocolloid before en bloc resection with extended lymphadenectomy.
  • Lower oesophageal tumours had a greater proportion of SLNs (P = 0.018), radioactive uptake (P < 0.001) and malignant nodes (P = 0.004) in the mediastinum than gastric cardia tumours.
  • CONCLUSION: The sentinel node concept is applicable to oesophageal adenocarcinoma and could be used to tailor the extent of lymphadenectomy.
  • There is a close relationship between patterns of radioactive uptake and lymphatic tumour dissemination, which differ for lower oesophageal and gastric cardia tumours.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15584066.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Hampel H, Abraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med; 2005 Aug 2;143(3):199-211
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of body mass index and gastroesophageal reflux disease (GERD), including its complications (esophagitis, Barrett esophagus, and esophageal adenocarcinoma), is unclear.
  • PURPOSE: To conduct a systematic review and meta-analysis to estimate the magnitude and determinants of an association between obesity and GERD symptoms, erosive esophagitis, Barrett esophagus, and adenocarcinoma of the esophagus and of the gastric cardia.
  • Six of 7 studies found significant associations of BMI with erosive esophagitis, 6 of 7 found significant associations with esophageal adenocarcinoma, and 4 of 6 found significant associations with gastric cardia adenocarcinoma.
  • Similarly, the pooled adjusted odds ratios for esophageal adenocarcinoma for BMI of 25 kg/m2 to 30 kg/m2 and BMI greater than 30 kg/m2 were 1.52 (CI, 1.147 to 2.009) and 2.78 (CI, 1.850 to 4.164), respectively.
  • CONCLUSION: Obesity is associated with a statistically significant increase in the risk for GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Esophagitis / etiology. Humans. Odds Ratio. Risk Factors


13. Chung JW, Lee GH, Choi KS, Kim DH, Jung KW, Song HJ, Choi KD, Jung HY, Kim JH, Yook JH, Kim BS, Jang SJ: Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification. Dis Esophagus; 2009;22(8):676-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification.
  • The incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing in Western countries.
  • We retrospectively reviewed the medical records of 16 811 patients diagnosed with esophageal squamous cell carcinoma (ESC, n= 1450) or gastric noncardiac adenocarcinoma (GNCA, n= 14 751) between 1992 and 2006.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222529.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Heinrich H, Bauerfeind P: Endoscopic mucosal resection for staging and therapy of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection for staging and therapy of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Endoscopic submucosal dissection (ESD) is a useful therapeutic option for HGD or early cancer in the squamous epithelium of the esophagus or in the stomach when en bloc resection is needed in large lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676873.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


15. Man XH, Xu Y, Wang ZN, Lü Z, Xu MD, Jiang L, Luo Y, Xu HM, Zhang X: [Loss of heterozygosity at chromosome 8p21-p23 in adenocarcinoma of gastric cardia]. Yi Chuan; 2006 Jun;28(6):641-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loss of heterozygosity at chromosome 8p21-p23 in adenocarcinoma of gastric cardia].
  • To investigate the involvement of the gene(s) in the carcinogenesis of adenocarcinoma of gastric cardia, loss of heterozygosity (LOH) for microsatellite markers at chromosome 8p21-p23 was examined.
  • Our data indicated that the tumor suppressor gene at chromosome 8p22 might play an important role in the development of adenocarcinoma of gastric cardia.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818423.001).
  • [ISSN] 0253-9772
  • [Journal-full-title] Yi chuan = Hereditas
  • [ISO-abbreviation] Yi Chuan
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


16. Zhang XH, Wang QZ: [Understanding and controversy of the gastroesophageal junction adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):947-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Understanding and controversy of the gastroesophageal junction adenocarcinoma].
  • [MeSH-major] Adenocarcinoma. Cardia. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174001.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 23
  •  go-up   go-down


17. von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR: Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol; 2005 Feb 1;23(4):874-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We prospectively evaluated 459 patients undergoing primary surgical resection for tumors of the esophagogastric junction at our institution between 1992 and 2000 (180 adenocarcinomas of the distal esophagus, AEG I; 140 carcinomas of the cardia, AEG II; and 139 subcardial gastric cancers, AEG III).
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681533.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


19. McColl KE: Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol; 2006;20(4):687-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the gastric cardia.
  • Current evidence indicates that cardia cancers are of at least two distinct and disparate aetiologies.
  • One type resembles cancer of the more distal stomach (Type A), being a consequence of atrophic gastritis due to Helicobacter pylori infection or more rarely autoimmune atrophic gastritis.
  • Another type (Type B) resembles oesophageal adenocarcinoma and is likely to be a consequence of short-segment gastro-oesophageal reflux disease.
  • The two cancers are themselves indistinguishable but examination of the gastric phenotype indicates the aetiology: Type A occurring in patients with evidence of atrophic gastritis whereas Type B occurs in subjects with healthy acid secreting stomachs.
  • In subjects with healthy acid secreting stomachs the cardia has a specific luminal chemistry remaining highly acidic and unbuffered following a meal and having very active nitrosative chemistry due to the acidification of nitrite in saliva.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997153.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


20. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A: Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer; 2009 Feb 10;100(3):551-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis.
  • Use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of gastric or oesophageal adenocarcinomas.
  • We examined the association between self-reported use of aspirin or non-aspirin NSAIDs in the earlier 12 months and gastric non-cardia (N=182), gastric cardia (N=178), and oesophageal adenocarcinomas (N=228) in a prospective cohort (N=311 115) followed for 7 years.
  • Use of any aspirin (HR, 95% CI: 0.64, 0.47-0.86) or other NSAIDs (0.68, 0.51-0.92) was associated with a significantly lower risk of gastric non-cardia adenocarcinoma.
  • Neither aspirin (0.86, 0.61-1.20) nor other NSAIDs (0.91, 0.67-1.22) had a significant association with gastric cardia cancer.
  • We found no significant association between using aspirin (1.00, 0.73-1.37) or other NSAIDs (0.90, 69-1.17) and oesophageal adenocarcinoma.
  • We also performed a meta-analysis of the association between the use of NSAIDs and risk of gastric and oesophageal adenocarcinoma.
  • In this analysis, aspirin use was inversely associated with both gastric and oesophageal adenocarcinomas, with summary odds ratios (95% CI) for non-cardia, cardia, and oesophageal adenocarcinomas of 0.64 (0.52-0.80), 0.82 (0.65-1.04), and 0.64 (0.52-0.79), respectively.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):202-7 [16450404.001]
  • [Cites] Digestion. 2006;74(2):109-15 [17167266.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):361-4 [17339621.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159.e3 [17644046.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107 [18095910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):126-34 [18187391.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):465-71 [18221867.001]
  • [Cites] Gut. 2008 May;57(5):561-7 [18194986.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78 [18483339.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321-31 [18446147.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):350-2 [18675670.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):119-23 [10667472.001]
  • [Cites] BMJ. 2000 Jun 17;320(7250):1642-6 [10856067.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Eur J Cancer Prev. 2000 Jun;9(3):185-91 [10954258.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):672-4 [12618872.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1687-92 [12771981.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1784-91 [14652240.001]
  • [Cites] BMC Cancer. 2003 Oct 31;3:28 [14588079.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55 [15352913.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3177-84 [15510608.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Epidemiology. 1994 Mar;5(2):138-46 [8172988.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):295-9 [8903469.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):473-6 [10404057.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4766-72 [16899628.001]
  • (PMID = 19156150.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Other-IDs] NLM/ PMC2658549
  •  go-up   go-down


21. Bastos J, Lunet N, Peleteiro B, Lopes C, Barros H: Dietary patterns and gastric cancer in a Portuguese urban population. Int J Cancer; 2010 Jul 15;127(2):433-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and gastric cancer in a Portuguese urban population.
  • We aimed to quantify the association between dietary patterns and gastric cancer, by location and histological type, according to Helicobacter pylori infection status.
  • We analyzed 591 incident cases of gastric adenocarcinoma and 1,463 community controls.
  • Compared to pattern I, the risk of gastric cancer was higher for pattern II (OR = 1.68, 95% CI: 1.31-2.14) but not for pattern III (OR = 0.80, 95% CI: 0.57-1.14), with no effect modification by H. pylori infection.
  • The association was similar for cardia and non-cardia gastric cancer, but for tumors of the diffuse Laurén histological type, the association was weaker for pattern II vs. I (OR = 1.32, 95% CI: 0.83-2.08) and a protective effect was observed for pattern III vs. I (OR = 0.43, 95% CI: 0.22-0.87).
  • [MeSH-major] Adenocarcinoma / epidemiology. Diet. Stomach Neoplasms / epidemiology. Urban Population / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia. Case-Control Studies. Female. Helicobacter Infections / complications. Helicobacter Infections / microbiology. Helicobacter pylori / isolation & purification. Humans. Male. Middle Aged. Nutrition Surveys. Portugal / epidemiology. Prognosis. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876925.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Cordin J, Lehmann K, Schneider PM: Clinical staging of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:73-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical staging of adenocarcinoma of the esophagogastric junction.
  • Upper endoscopy establishes the tumor diagnosis by multiple biopsies and defines the tumor type (Siewert I-III), based on tumor localization in relation to the endoscopic cardia.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676872.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


23. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH: Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control; 2009 Apr;20(3):361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.
  • A number of risk factors for esophageal and gastric cancers have emerged, yet little is known whether risk factors map to molecular tumor markers such as overexpression of the tumor suppressor TP53.
  • Using a US multicenter, population-based case-control study (170 cases of esophageal adenocarcinomas, 147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, and 112 esophageal squamous cell carcinomas), we examined whether the risk associated with cigarette smoking, body mass index (BMI), gastroesophageal reflux disease (GERD), and non-steroidal anti-inflammatory drug (NSAID) use varied by P53 overexpression.
  • The proportion of cases overexpressing P53 by tumor subtype was 72% for esophageal adenocarcinoma, 69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67% for esophageal squamous cell carcinoma.
  • For non-cardia gastric cancer however, an association with cigarette smoking was suggested for tumors that do not overexpress P53, whereas larger BMI was related to adenocarcinomas that overexpress P53 versus no overexpression.
  • Overall, this study did not find a clear relationship between P53 protein overexpression and the known risk factors for subtypes of esophageal and gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Vojnosanit Pregl. 2005 Dec;62(12):879-85 [16375215.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2914-8 [8187077.001]
  • [Cites] Carcinogenesis. 1995 May;16(5):993-1002 [7767998.001]
  • [Cites] Pathol Res Pract. 1994 Dec;190(12):1141-8 [7540752.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):425-32 [9028350.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Mod Pathol. 2001 May;14(5):397-403 [11353048.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):233-40 [11902578.001]
  • [Cites] Oncology. 2002;62(2):175-9 [11914604.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1729-35 [14583777.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):779-82 [9332759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1065-9 [9419404.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Cancer. 1998;77(2):277-86 [9460999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):591-7 [10223186.001]
  • [Cites] J Pathol. 1999 Jan;187(1):8-18 [10341702.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):63-8 [15621992.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):225-30 [15765441.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • (PMID = 18989634.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] None / None / / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; None / None / / U01 CA057983-03; United States / Intramural NIH HHS / / Z01 CP010136-12; United States / NCI NIH HHS / CA / U01 CA057923; United States / NCI NIH HHS / CA / U01 CA 57923; United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NCI NIH HHS / CA / U01 CA 57983; United States / NCI NIH HHS / CA / U01 CA 57049; None / None / / U01 CA057949-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS100106; NLM/ PMC2726999
  •  go-up   go-down


24. Wang N, Dong XJ, Zhou RM, Guo W, Zhang XJ, Li Y: An investigation on the polymorphisms of two DNA repair genes and susceptibility to ESCC and GCA of high-incidence region in northern China. Mol Biol Rep; 2009 Feb;36(2):357-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the possible association of three SNPs, XRCC2 C41657T, XRCC2 G4234C and XRCC3 A17893G with susceptibility to esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA) in a population of northern China.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. DNA Repair / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22148-53 [11301337.001]
  • [Cites] Curr Opin Genet Dev. 2000 Apr;10(2):144-50 [10753787.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):916-24 [16361273.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1615-23 [12883749.001]
  • [Cites] Carcinogenesis. 2004 Feb;25(2):189-95 [14578164.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):494-500 [10677309.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):757-61 [11025669.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2633-8 [10541549.001]
  • [Cites] J Clin Pathol. 2002 Aug;55(8):587-90 [12147651.001]
  • [Cites] Cancer Lett. 2005 Mar 10;219(2):125-35 [15723711.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] EMBO J. 1998 Sep 15;17 (18):5497-508 [9736627.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):681-4 [10048966.001]
  • [Cites] J Cell Biochem. 2004 Oct 15;93(3):429-36 [15372620.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3296-307 [11751635.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1399-407 [12023982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1345-50 [15668400.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8181-7 [14678973.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2268-74 [2317814.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1054-64 [12376507.001]
  • [Cites] World J Gastroenterol. 2000 Jun;6(3):374-376 [11819601.001]
  • [Cites] Mutat Res. 2000 Mar 20;459(2):89-97 [10725659.001]
  • [Cites] Mol Cell. 1998 May;1(6):783-93 [9660962.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6354-8 [7603995.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):611-8 [15924337.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1430-5 [15817609.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):247-54 [11242102.001]
  • [Cites] BMC Cancer. 2005 Jan 28;5:12 [15679883.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21482-8 [9705276.001]
  • [Cites] Nature. 1999 Sep 23;401(6751):397-9 [10517641.001]
  • [Cites] Int J Epidemiol. 1994 Jun;23(3):444-50 [7960367.001]
  • (PMID = 18046624.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 3; 0 / XRCC2 protein, human
  •  go-up   go-down


25. Isgüder AS, Nazli O, Tansug T, Bozdag AD, Onal MA: Total gastrectomy for gastric carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for gastric carcinoma.
  • BACKGROUND/AIMS: Gastric cancer is one of the most common organ cancers all around the world and surgical resection is essential for treatment.
  • Total gastrectomy is the procedure of choice for treatment of proximal gastric cancer.
  • METHODOLOGY: Thirty-eight gastric cancer patients underwent total gastrectomy in the Third Surgical Clinic of Izmir Ataturk Training and Research Hospital between 1996 and 2001.
  • Sites of the tumors were: cardia 28.9%, cardia and corpus 15.8%, corpus 34.3%, corpus and antrum 18.4%, linitis plastica 2.6%.
  • Histological types were adenocarcinoma (97.4%), and squamous cell carcinoma (2.6%).
  • Gastric tubes were removed on the fourth postoperative day.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Langman M, Logan R: Risk of cancer and acid suppressant treatment. Gut; 2007 Jul;56(7):1023
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antacids / adverse effects. Esophageal Neoplasms / chemically induced. Stomach Neoplasms / chemically induced
  • [MeSH-minor] Anti-Ulcer Agents / adverse effects. Cardia. Humans. Research Design

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2003 Jul;52(7):942-6 [12801948.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 May 28;286(6379):1713-6 [6405946.001]
  • [CommentOn] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • (PMID = 17566037.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antacids; 0 / Anti-Ulcer Agents
  • [Other-IDs] NLM/ PMC1994362
  •  go-up   go-down


27. Bor S, Vardar R, Ormeci N, Memik F, Suleymanlar I, Oguz D, Colakoglu S, Yucesoy M, Turkdogan K, Gurel S, Dogan I, Yildirim B, Goral V, Dokmeci G, Okcu N, Duman D, Simsek I, Demir A: Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol; 2007 Dec;22(12):2242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori.
  • AIM: In developed countries, there has been a recent increase in the prevalence of adenocarcinoma of the esophagus and cardia, along with a decrease in distal gastric cancers.
  • The aim of the present study was to evaluate changes in the prevalence of gastric adenocarcinomas in Turkey as a function of anatomic location.
  • Owing to the exclusion criteria, a total of 4065 cases of tumors of the stomach and distal esophagus were included.
  • The ratio of distal/proximal adenocarcinoma was 2,1 [corrected] for the western part of Turkey and 3,8 [corrected] for the eastern part of the country (P < 0.0001), and this did not change during the 11 years. H. pylori was detected significantly less in the west compared to the east for distal tumors (65.7 vs 38.7%, respectively, P = 0.02).
  • CONCLUSION: In Turkey, a developing country with a high H. pylori prevalence, contrary to the state of developed countries, the ratio of distal versus proximal gastric adenocarcinomas has not changed.
  • Geographical distribution should be taken into the account in projecting the changing patterns of gastric cancers.
  • [MeSH-major] Developing Countries. Helicobacter pylori. Stomach Neoplasms / epidemiology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1309
  • (PMID = 18031388.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR: Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol; 2007 Apr;14(4):1312-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen preservation in radical surgery for gastric cardia cancer.
  • BACKGROUND: In gastric cardia cancer (GCC), the spleen is usually removed when the tumor is resected.
  • The purpose of this study was to investigate the effect of spleen preservation on survival following radical resection for gastric cardia cancer.
  • CONCLUSIONS: Splenectomy does not improve survival of patients who undergo curative resection for gastric cardia cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Spleen / physiology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265118.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Huerta JM, Navarro C, Chirlaque MD, Tormo MJ, Steindorf K, Buckland G, Carneiro F, Johnsen NF, Overvad K, Stegger J, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Boeing H, Kaaks R, Rohrmann S, Vigl M, Lagiou P, Trichopoulos D, Trichopoulou A, Bas Bueno-de-Mesquita H, Monninkhof EM, Numans ME, Peeters PH, Mattiello A, Pala V, Palli D, Tumino R, Vineis P, Agudo A, Ardanaz E, Arriola L, Molina-Montes E, Rodríguez L, Lindkvist B, Manjer J, Stenling R, Lund E, Crowe FL, Key TJ, Khaw KT, Wareham NJ, Jenab M, Norat T, Romaguera D, Riboli E, González CA: Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort. Cancer Causes Control; 2010 May;21(5):657-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort.
  • OBJECTIVE: To analyse the association between types of physical activity (occupational, recreational and household, vigorous and overall) and risk of primary oesophageal (OAC) or gastric adenocarcinoma (GAC).
  • Analyses were repeated by tumour site (cardia/non-cardia) and histological type (intestinal/diffuse).
  • A lower risk of overall and non-cardia GAC was found for increasing levels of a PA index which combined occupational PA with weekly time spent in sports and cycling.
  • The hazard ratio (HR) of GAC was 0.69, 95% CI: 0.50-0.94, for the comparison between active and inactive participants according to the PA index (HR = 0.44, 95% CI:0.26-0.74, for non-cardia GAC).
  • No effect was found for cardia tumours or histological subtypes of GAC.
  • CONCLUSIONS: Overall and distal (non-cardia) gastric tumours were inversely associated with time spent on cycling and sports and a total PA index.
  • No association was found for any type of PA and risk of cardia cancers of the stomach.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Exercise. Health Behavior. Nutrition Surveys. Stomach Neoplasms / epidemiology


30. Trouillet N, Robert B, Charfi S, Bartoli E, Joly JP, Chatelain D: Gastric metastases. An endoscopic series of ten cases. Gastroenterol Clin Biol; 2010 Apr-May;34(4-5):305-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric metastases. An endoscopic series of ten cases.
  • We report a series of ten cases of the clinical, endoscopic and pathological features of gastric metastases.
  • Patients were six women and four men between 54 and 88 years old, with gastric metastases from breast carcinoma (4), lung carcinoma (4) and melanoma (2).
  • Metastases were located in the cardia (2), fundus (5) and antrum (3).
  • The microscopic features of the gastric metastases resembled a primary gastric cancer in eight cases.
  • Thanks to clinical data, the pathologist confirmed the diagnosis of gastric metastases on immunohistochemistry.
  • Gastric metastases are rare, occur at a late stage of the neoplastic disease, and have a poor prognosis.
  • Diagnosis of gastric metastases is difficult because they simulate primary gastric cancer on endoscopy and on microscopic examination.
  • [MeSH-major] Endoscopy, Gastrointestinal. Stomach Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627637.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. DiMusto PD, Orringer MB: Transhiatal esophagectomy for distal and cardia cancers: implications of a positive gastric margin. Ann Thorac Surg; 2007 Jun;83(6):1993-8; discussion 1998-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transhiatal esophagectomy for distal and cardia cancers: implications of a positive gastric margin.
  • BACKGROUND: A common operation for cancer of the esophagus and cardia consists of transhiatal esophagectomy, proximal gastrectomy, and a cervical esophagogastric anastomosis.
  • The oncologic adequacy of dividing the stomach 4 to 6 cm distal to palpable tumor is not well documented, and when a positive gastric margin is present on the final pathologic analysis, the appropriate management is not established.
  • This study was undertaken to determine the incidence of a positive gastric margin in these patients and the impact of adjuvant treatment.
  • METHODS: A retrospective review was performed of 1044 patients undergoing transhiatal esophagectomy for adenocarcinoma of the distal esophagus or cardia.
  • Twenty (1.9%) had a positive gastric margin on final the pathologic evaluation and met inclusion criteria for this study.
  • CONCLUSIONS: A transhiatal esophagectomy and proximal gastrectomy for carcinoma of the distal esophagus and cardia, dividing the stomach 4 to 6 cm from palpable tumor, provides a negative gastric margin in 98% of patients.
  • In the few patients who have a positive gastric margin, 80% die with distant metastases, which would not be influenced by more extensive gastric resection, and in about 20%, local tumor recurrence develops in the intrathoracic stomach, seldom causing dysphagia.
  • Adjuvant therapy for a positive gastric margin neither improves survival nor reduces local tumor recurrence.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Anastomosis, Surgical. Cardia / surgery. Combined Modality Therapy. Deglutition Disorders / prevention & control. Esophagus / surgery. Gastrectomy / methods. Humans. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies. Stomach / surgery. Survival Analysis


32. Sadighi S, Raafat J, Mohagheghi M, Meemary F: Gastric carcinoma: 5 year experience of a single institute. Asian Pac J Cancer Prev; 2005 Apr-Jun;6(2):195-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric carcinoma: 5 year experience of a single institute.
  • PURPOSE: Gastric cancer (GC) is the most common cause of cancer death registered in cancer institute.
  • Most common site of involvement was cardia (43%).
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101332.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


33. Guo W, Cui YJ, Fang SM, Li Y, Wang N, Zhang JH: [Association of polymorphisms of p21cip1 and p27kip1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. Ai Zheng; 2006 Feb;25(2):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of polymorphisms of p21cip1 and p27kip1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
  • This study was to investigate the possible association of functional polymorphisms of p21(cip1) and p27(kip1) genes with susceptibilities of esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in a population from a high incidence region in north China.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Esophageal Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Cardia. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Smoking

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480585.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


34. Hida Y, Kubo Y, Nishio Y, Murakami S, Fukumoto D, Sayama K, Hashimoto K, Arase S: Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. Acta Derm Venereol; 2009;89(4):435-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / complications. Aged. Cardia. Fatal Outcome. Humans. Hypertrophy. Immunohistochemistry. Male. Skin / pathology. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688170.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Sweden
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


35. Sampliner RE, Camargo E, Prasad AR: Association of ablation of Barrett's esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia. Dis Esophagus; 2006;19(4):277-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ablation of Barrett's esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia.
  • Three cases are reported in which the patient developed adenocarcinoma of the gastric cardia after thermal ablation of HGD.
  • Three cases are reported with long-segment BE and a nodule or mass in the endoscopic cardia post-thermal ablation.
  • Biopsies documented adenocarcinoma of the gastric cardia.
  • The development of adenocarcinoma of the cardia is unexpected.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866860.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Capellá G, Pera G, Sala N, Agudo A, Rico F, Del Giudicce G, Plebani M, Palli D, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Berrino F, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key T, Bingham S, Caldas C, Linseisen J, Nagel G, Overvad K, Tjonneland A, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Kaaks R, Riboli E, González CA: DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol; 2008 Dec;37(6):1316-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study.
  • BACKGROUND: The contribution of genetic variation in DNA repair genes to gastric cancer (GC) risk remains essentially unknown.
  • Method A nested case control study within the EPIC cohort was performed including 246 gastric adenocarcinomas and 1175 matched controls.
  • RESULTS: No association was observed for any of these polymorphisms with stomach cancer risk.
  • This is the first prospective study suggesting that individual variation in DNA repair may be relevant for gastric carcinogenesis, a finding that will require further confirmation validation in larger independent studies.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Repair / genetics. Gastritis, Atrophic / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Antibodies, Bacterial / blood. Biomarkers / blood. Cardia / pathology. Case-Control Studies. Chronic Disease. Europe. Female. Follow-Up Studies. Gene Frequency. Genes, p53. Genetic Predisposition to Disease. Helicobacter Infections / complications. Helicobacter Infections / immunology. Helicobacter pylori / immunology. Humans. Male. Middle Aged. Odds Ratio. Pepsinogen A / blood. Prospective Studies. Risk. Xeroderma Pigmentosum Group D Protein / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641418.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Biomarkers; 9001-10-9 / Pepsinogen A; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


37. Wen D, Shan B, Wang S, Zhang L, Wei L, Zhou W, Peng Q: A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area. Eur J Med Genet; 2010 Sep-Oct;53(5):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area.
  • BACKGROUND: To find a genetic component in gastric cardia adenocarcinomas (GCA).
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group. Cardia / pathology. Esophageal Neoplasms / genetics. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20603233.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


38. Mottershead M, Karteris E, Barclay JY, Suortamo S, Newbold M, Randeva H, Nwokolo CU: Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma. J Clin Pathol; 2007 Apr;60(4):405-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma.
  • BACKGROUND: Ghrelin is an orexigenic gut peptide produced predominantly by the stomach.
  • Gastric mucosal ghrelin production could be compromised by an infiltrating adenocarcinoma.
  • METHODS: 10 gastric and 22 oesophageal adenocarcinoma archival samples were randomly selected from a database.
  • Quantitative reverse transcriptase polymerase chain reaction (PCR) for ghrelin mRNA was also performed on 24 gastric and 8 oesophageal adenocarcinoma specimens and adjacent non-neoplastic mucosa.
  • RESULTS: Immunohistochemistry and reverse transcriptase PCR confirm a negligible expression of ghrelin in adenocarcinoma specimens.
  • By contrast, non-neoplastic gastric mucosa was rich in ghrelin-positive cells and ghrelin mRNA.
  • The number (median and range) of ghrelin-positive cells per 2 mm section of non-neoplastic mucosa was 73 (45-215) in the corpus; this was significantly higher than in cardia mucosa (9 (0-64), p<0.001) and antral mucosa (5 (0-14), p<0.001).
  • CONCLUSIONS: Gastric and oesophageal adenocarcinomas have no ghrelin-producing cells.
  • The highest level of ghrelin expression was noted in the non-neoplastic mucosa of the gastric corpus.
  • Disruption of the gastric ghrelin-producing mechanism may occur during oesophagogastric malignancy.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Peptide Hormones / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Gastric Mucosa / metabolism. Ghrelin. Humans. Immunoenzyme Techniques. Neurosecretory Systems / metabolism. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Dec 9;402(6762):656-60 [10604470.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1623-30 [12023994.001]
  • [Cites] Nature. 2000 Oct 19;407(6806):908-13 [11057670.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4255-61 [11089560.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4908-11 [11134161.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):194-8 [11196643.001]
  • [Cites] Eur J Endocrinol. 2000 Dec;143(6):R11-4 [11124868.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):788-94 [11159851.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):881-7 [11158061.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1464-9 [11297568.001]
  • [Cites] Trends Endocrinol Metab. 2001 Apr;12(3):118-22 [11306336.001]
  • [Cites] J Endocrinol Invest. 2001 Jun;24(6):RC19-21 [11434675.001]
  • [Cites] Diabetes. 2001 Aug;50(8):1714-9 [11473029.001]
  • [Cites] Gut. 2002 Jun;50 Suppl 5:v1-23 [12049068.001]
  • [Cites] Histochem Cell Biol. 2002 Jun;117(6):511-9 [12107501.001]
  • [Cites] Histochem Cell Biol. 2002 Jun;117(6):521-5 [12107502.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1120-8 [12360474.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):774-8 [12576449.001]
  • [Cites] Diabetes. 2003 Apr;52(4):948-56 [12663466.001]
  • [Cites] Gut. 2003 Jul;52(7):947-52 [12801949.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):143-61 [12831935.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3117-20 [12843152.001]
  • [Cites] Gut. 2003 Oct;52(10):1391-2 [12970126.001]
  • [Cites] FEBS Lett. 2003 Sep 25;552(2-3):105-9 [14527669.001]
  • [Cites] Gut. 2004 Feb;53(2):187-94 [14724148.001]
  • [Cites] Eur J Cancer. 1991;27(1):9-15 [1826450.001]
  • [Cites] Ann Surg. 1994 Apr;219(4):325-31 [7512810.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):277-87 [9208884.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1293-7 [9260792.001]
  • [Cites] Biotech Histochem. 2005 May-Aug;80(3-4):163-8 [16298902.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4753-8 [11600536.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):5052-9 [11600584.001]
  • [Cites] Diabetes. 2001 Nov;50(11):2540-7 [11679432.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5992 [11739476.001]
  • [Cites] Peptides. 2002 Mar;23(3):531-6 [11836003.001]
  • [Cites] J Endocrinol Invest. 2000 Sep;23(8):493-5 [11021763.001]
  • (PMID = 16751299.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2001112
  •  go-up   go-down


39. Cao YY, Ge H, Chen LQ, Chen ZF, Wen DG, Li Y, Zhang JH: [Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. Ai Zheng; 2007 Oct;26(10):1052-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
  • This study was to investigate the correlation of 53BP1 and p53 SNPs to susceptibility to esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in a high incidence area of Hebei Province in China.
  • [MeSH-major] Cardia. Esophageal Neoplasms / genetics. Intracellular Signaling Peptides and Proteins / genetics. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Alleles. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. China / epidemiology. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927872.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / TP53BP1 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


40. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH: Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol; 2006 Jun 28;12(24):3883-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia.
  • AIM: To investigate the influence of a positive proximal margin in total gastrectomy patients with gastric adenocarcinoma of the cardia.
  • METHODS: Medical records of 191 patients with total gastrectomies for adenocarcinoma of the cardia between 1995 and 2000 were reviewed.
  • CONCLUSION: A positive margin is more of an indication of advanced disease in patients with gastric adenocarcinoma of the cardia rather than an independent prognostic factor for survival.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cardia / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1977 Apr;144(4):563-6 [847612.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] Am J Surg. 1980 May;139(5):711-3 [7468923.001]
  • [Cites] Ann Surg. 1982 Dec;196(6):685-90 [7149820.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10):700-3 [11021482.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1773-6 [11037842.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):810-4 [11087650.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):588-93 [12943624.001]
  • [Cites] Curr Probl Surg. 1973 Nov;:3-72 [4592910.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):247-50 [3629439.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1347-51 [3675199.001]
  • [Cites] J Surg Oncol. 1989 Mar;40(3):162-9 [2465454.001]
  • [Cites] Ann Acad Med Singapore. 1989 Jan;18(1):69-71 [2712522.001]
  • [Cites] J Surg Oncol. 1989 Nov;42(3):170-4 [2811381.001]
  • [Cites] Acta Chir Scand. 1990 Feb;156(2):127-30 [2330791.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):60-3 [8479199.001]
  • [Cites] Br J Surg. 1993 Nov;80(11):1418-20 [8252353.001]
  • [Cites] Am J Surg. 1995 Mar;169(3):316-9 [7879834.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):873-7 [8847038.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):433-7 [8814687.001]
  • [Cites] Aust N Z J Surg. 1996 Nov;66(11):734-7 [8918379.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Surg. 1981 Feb;68(2):73-4 [7459624.001]
  • (PMID = 16804975.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087938
  •  go-up   go-down


41. Vissers KJ, Dinjens WN, Riegman PH, Tilanus HW, van Dekken H: Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. Anticancer Res; 2005 Mar-Apr;25(2A):913-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma.
  • BACKGROUND: Oesophageal (Barrett's) and gastric cardia adenocarcinomas are cancers arising at and around the gastro-oesophageal junction.
  • In addition, 40 gastric cardia cancers were investigated to compare the pattern of imbalance at these loci.
  • RESULTS: Overall, the number of allelic loss was higher in Barrett's cancers than in gastric cardia carcinomas (p=0.04).
  • In gastric cardia cancers, loss ranged from 12% to 27% (of informative cases), being most frequent at marker D7S3037.
  • The difference between oesophageal and gastric adenocarcinomas was highest for polymorphic marker D7S483 (p=0.05).
  • CONCLUSION: Marker D7S483 can aid in discriminating oesophageal (Barrett's) and gastric cardia carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Barrett Esophagus / genetics. Cardia / pathology. Chromosomes, Human, Pair 7 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868927.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


42. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, Schatzkin A: A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol; 2007 Jun 15;165(12):1424-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes.
  • Rates of esophageal adenocarcinoma and gastric cardia adenocarcinoma have increased, while rates of esophageal squamous cell carcinoma (ESCC) and gastric noncardia adenocarcinoma have decreased, suggesting distinct etiologies.
  • Between 1995/1996 and 2000, 97 incident cases of ESCC, 205 of esophageal adenocarcinoma, 188 of gastric cardia, and 187 of gastric noncardia cancer occurred.
  • Compared with nonsmokers, current smokers were at increased risk for ESCC (hazard ratio (HR) = 9.27, 95% confidence interval (CI): 4.04, 21.29), esophageal adenocarcinoma (HR = 3.70, 95% CI: 2.20, 6.22), gastric cardia (HR = 2.86, 95% CI: 1.73, 4.70), and gastric noncardia (HR = 2.04, 95% CI: 1.32, 3.16).
  • Assuming causality, ever smoking had population attributable risks of 77% (95% CI: 0.55, 0.89) for ESCC, 58% (95% CI: 0.38, 0.72) for esophageal adenocarcinoma, 47% (95% CI: 0.27, 0.63) for gastric cardia, and 19% (95% CI: 0.00, 0.37) for gastric noncardia.
  • For drinkers of more than three alcoholic beverages per day, compared with those whose intake was up to one drink per day, the authors found significant associations between alcohol intake and ESCC risk (HR = 4.93, 95% CI: 2.69, 9.03) but not risk for esophageal, gastric cardia, or gastric noncardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Alcohol Drinking / adverse effects. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Smoking / adverse effects. Stomach Neoplasms / etiology


43. Steevens J, Botterweck AA, Dirx MJ, van den Brandt PA, Schouten LJ: Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol; 2010 Jun;22(6):669-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence of oesophageal and stomach cancer subtypes in Europe.
  • OBJECTIVE: Time trend studies in the USA have shown that the incidences of adenocarcinomas of the oesophagus and gastric cardia have risen strongly since the 1970s, whereas the incidence of squamous cell carcinomas of the oesophagus has declined.
  • The main goal of this study was to investigate more recent trends in the incidence of oesophageal and stomach cancer subtypes in the European countries.
  • METHODS: Eurocim cancer incidence data of 23 cancer registries from 13 European countries were used to investigate the incidence trends in oesophageal and stomach cancer subtypes during the 1983-1997 period.
  • RESULTS: The incidence of adenocarcinomas of the oesophagus and gastric cardia rose in most, but not all, registration areas (EAPCs were usually 1-7%), the strongest in the UK and Ireland.
  • CONCLUSION: Our results are partly in line with earlier findings on adenocarcinomas of the oesophagus and gastric cardia.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Neoplasms, Squamous Cell / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474750.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE, Sarbia M: Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol; 2005 Dec;131(12):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using PCR based restriction fragment length polymorphism and single strand conformational polymorphism, we determined single nucleotide exchanges in the p16 and cyclin D1 genes among 56 esophageal adenocarcinomas (ADC) arising in Barrett's esophagus, 95 cardiac gastric ADC, and in 191 distal gastric ADC.
  • RESULTS: The C/G genotype of p16 was identified in 10.4% of esophageal carcinomas, 13.3% of cardiac carcinomas, and in 14.1% of gastric carcinomas, compared to 17.4% in the healthy control group.
  • In distal gastric carcinoma, both homozygous genotypes (G/G and A/A) had a frequency of 15.2% each, while the heterozygous A/G genotype occurred in 69.6% of patients.
  • CONCLUSIONS: Our results show that frequencies of p16 or cyclin D1 polymorphisms in gastric and esophageal ADC do not differ significantly from the healthy control group.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Esophageal Neoplasms / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine. Barrett Esophagus / complications. Cardia. Case-Control Studies. Cysteine. DNA, Neoplasm / analysis. Female. Gene Frequency. Glycine. Homozygote. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Polymorphism, Single Nucleotide. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1195-9 [11470749.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):176 [12582032.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):404-14 [10862049.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):640-5 [12101111.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):1005-11 [7675441.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):476-86 [15297940.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1499-503 [12807740.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):98-103 [12532425.001]
  • [Cites] Int J Cancer. 2004 Mar;109(1):138-43 [14735480.001]
  • [Cites] Int J Cancer. 1998 Jan 19;75(2):193-8 [9462707.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Urology. 2004 Jul;64(1):74-8 [15245939.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1007-10 [11490786.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):281-4 [12673692.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77 [9823374.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1405 [12151361.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2843-8 [14657069.001]
  • (PMID = 16163549.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 136601-57-5 / Cyclin D1; K848JZ4886 / Cysteine; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


45. Nomura AM, Kolonel LN, Miki K, Stemmermann GN, Wilkens LR, Goodman MT, Perez-Perez GI, Blaser MJ: Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis; 2005 Jun 15;191(12):2075-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii.
  • BACKGROUND: The objective was to investigate the association of Helicobacter pylori and serum pepsinogen (PG) levels with gastric adenocarcinoma.
  • RESULTS: Subjects with low PG I levels or low PG I/II ratios were at increased risk for cardia and noncardia gastric cancer, whereas those with H. pylori or CagA seropositivity had an elevated risk for noncardia cancer only.
  • CONCLUSIONS: The results suggest that persons with both H. pylori or CagA seropositivity and a low PG I level or PG I/II ratio are highly susceptible to development of noncardia gastric cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori / pathogenicity. Pepsinogen A / blood. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897993.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 33619
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori; 9001-10-9 / Pepsinogen A
  •  go-up   go-down


46. Alvarez Herrero L, Pouw RE, van Vilsteren FG, ten Kate FJ, Visser M, van Berge Henegouwen MI, Weusten BL, Bergman JJ: Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy; 2010 Dec;42(12):1030-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens.
  • BACKGROUND: Most risk estimations for lymph node metastasis in adenocarcinoma of the esophagus and cardia (AEC) with invasion into the muscularis mucosae (m3) or submucosa are based on surgical series.
  • [MeSH-major] Adenocarcinoma / secondary. Cardia / pathology. Esophageal Neoplasms / pathology. Mucous Membrane / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20960392.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


47. Zhang XH: [Adenocarcinoma arising in gastroesophageal junction: a reappraisal]. Zhonghua Bing Li Xue Za Zhi; 2007 Jun;36(6):363-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma arising in gastroesophageal junction: a reappraisal].
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822618.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 31
  •  go-up   go-down


48. Ryan AM, Rowley SP, Fitzgerald AP, Ravi N, Reynolds JV: Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity. Eur J Cancer; 2006 May;42(8):1151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity.
  • Recent evidence links obesity with the rising incidence of oesophageal adenocarcinoma.
  • In Ireland between 1995 and 2004 the incidence of oesophageal adenocarcinoma increased by 38%, and this coincided with a 67% increase in the prevalence of obesity.
  • In this study, a prospective case-control study was undertaken in 760 patients presenting to a tertiary centre between 1994 and 2004 diagnosed with cancer of the oesophagus, gastric cardia or stomach.
  • Based on pre-illness BMI, 82% of patients who developed adenocarcinoma of the oesophagus were either overweight or obese compared with 59% of the healthy control population (P<0.001).
  • A dose-dependent relationship existed between BMI and oesophageal adenocarcinoma in males.
  • Using common cut-off points for BMI, the OR of adenocarcinoma of the lower oesophagus was 11.3 times higher (95% CI: 3.5-36.4) for individuals with a BMI >30 kg/m2 versus individuals with a BMI <22 kg/m2 (P<0.001 for trend).
  • For adenocarcinoma of the gastric cardia, males in the top quartile of BMI had an OR of 3.5 (95% CI: 1.3-9.4) compared with the lowest quartile (P=0.03 for trend).
  • The odds ratio for adenocarcinoma of the oesophagus, the oesophago-gastric junction and gastric cardia rose significantly with increasing BMI.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Cardia. Esophageal Neoplasms / etiology. Obesity / complications. Stomach Neoplasms / etiology


49. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J, Asia-Pacific Gastric Cancer Consensus Conference: Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol; 2008 Mar;23(3):351-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asia-Pacific consensus guidelines on gastric cancer prevention.
  • BACKGROUND AND AIM: Gastric cancer is a major health burden in the Asia-Pacific region but consensus on prevention strategies has been lacking.
  • We aimed to critically evaluate strategies for preventing gastric cancer.
  • RESULTS: Helicobacter pylori infection is a necessary but not sufficient causal factor for non-cardia gastric adenocarcinoma.
  • A high intake of salt is strongly associated with gastric cancer.
  • Fresh fruits and vegetables are protective but the use of vitamins and other dietary supplements does not prevent gastric cancer.
  • Host-bacterial interaction in H. pylori infection results in different patterns of gastritis and differences in gastric acid secretion which determine disease outcome.
  • A positive family history of gastric cancer is an important risk factor.
  • Low serum pepsinogens reflect gastric atrophy and may be useful as a marker to identify populations at high risk for gastric cancer. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high-risk populations. H. pylori screening and treatment is most effective before atrophic gastritis has developed.
  • It does not exclude the existing practice of gastric cancer surveillance in high-risk populations.
  • In populations at low risk for gastric cancer, H. pylori screening is not recommended.
  • CONCLUSION: A strategy of H. pylori screening and eradication in high-risk populations will probably reduce gastric cancer incidence, and based on current evidence is recommended by consensus.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Biomarkers, Tumor / analysis. Helicobacter Infections / drug therapy. Helicobacter pylori. Mass Screening. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318820.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Pepsinogens; 0 / Sodium Chloride, Dietary; 0 / Vitamins; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 140
  •  go-up   go-down


50. Ghotli ZA, Serra S, Chetty R: Clear cell (glycogen rich) gastric adenocarcinoma: a distinct tubulo-papillary variant with a predilection for the cardia/gastro-oesophageal region. Pathology; 2007 Oct;39(5):466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell (glycogen rich) gastric adenocarcinoma: a distinct tubulo-papillary variant with a predilection for the cardia/gastro-oesophageal region.
  • AIMS: To explore the clinicopathological and immunohistochemical profile of clear cell gastric cancers with a tubulo-papillary pattern.
  • METHODS: Twelve cases of clear cell gastric cancer (containing a minimum of 10% of clear cells) were studied.
  • Ten cases were located in the gastric cardia with extension into the gastro-oesophageal junction and two were in the pylorus/pre-pyloric area.
  • CONCLUSION: Clear cell gastric cancers have a predilection for the gastro-oesophageal junction, are polypoid, have a tubulopapillary pattern, and show over-expression of cyclin D1 but normal E-cadherin.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cardia / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology


51. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ: Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep; 2010 Jan;37(1):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China.
  • The aim of the present study was to investigate the association of single nucleotide polymorphisms (SNPs) in matrix metalloproteinase (MMPs) with the risk of gastric cardia adenocarcinoma (GCA) and esophageal squamous cell carcinoma (ESCC).
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinases / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / epidemiology. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. China / epidemiology. Female. Gene Frequency / genetics. Haplotypes / genetics. Humans. Incidence. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1117-21 [15731163.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7549-58 [11114309.001]
  • [Cites] Matrix Biol. 2002 Oct;21(6):487-98 [12392760.001]
  • [Cites] Circ Res. 2000 May 12;86(9):998-1003 [10807873.001]
  • [Cites] Br Heart J. 1995 Mar;73(3):209-15 [7727178.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] Lung Cancer. 2007 May;56(2):273-80 [17208328.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7622-8 [15492291.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2519-24 [15319302.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2614-20 [17473191.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1834-9 [11701474.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3820-3 [12473595.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1024-9 [16311244.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):197-204 [15609121.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gynecol Obstet Invest. 2008;65(1):68-72 [17851253.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2385-9 [15832405.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):405-9 [15250832.001]
  • [Cites] FEBS Lett. 1996 Feb 12;380(1-2):17-20 [8603731.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1748-53 [15930031.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3987-90 [12873995.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):415-33 [11170864.001]
  • [Cites] Biochem Genet. 2008 Apr;46(3-4):137-44 [18210196.001]
  • (PMID = 19562509.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


52. Tsavaris N, Kosmas C, Kopterides P, Tsikalakis D, Skopelitis H, Sakelaridi F, Papadoniou N, Tzivras M, Balatsos V, Koufos C, Archimandritis A: Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J Gastroenterol; 2005 Dec 7;11(45):7174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma.
  • AIM: To determine the serum levels of c-reactive protein (CRP), transferrin (TRF), a2-macroglobulin (A2M), ceruloplasmin (CER), a1-acid glycoprotein (AAG), pre-albumin (P-ALB) and retinol-binding protein (RBP) in gastric carcinoma patients and to explore their possible correlation with underlying Helicobacter pylori (H pylori) infection.
  • METHODS: We measured the serum levels of CRP, TRF, A2M, CER, AAG, P-ALB, and RBP in 153 preoperative patients (93 males; mean age: 63.1+/-11.3 years) with non-cardia gastric adenocarcinoma and 19 healthy subjects.
  • Retinol-binding protein seems to discriminate between infected and non-infected patients with gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437667.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / Retinol-Binding Proteins
  • [Other-IDs] NLM/ PMC4725071
  •  go-up   go-down


53. Mandong BM, Manasseh AN, Tanko MN, Echejoh GO, Madaki AJ: Epidemiology of gastric cancer in Jos University Teaching Hospital Jos a 20 year review of cases. Niger J Med; 2010 Oct-Dec;19(4):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of gastric cancer in Jos University Teaching Hospital Jos a 20 year review of cases.
  • BACKGROUND: Gastric cancer believed to be rare in the past in Africa, is now one of the leading cancer morbidity and mortality.
  • It is now known gastric cancer is 2-3 times higher in males than females living in the same environment.
  • We aim to describe the comprehensive histological characteristics of gastric cancer with age and sex distribution.
  • The study materials were obtained from all stained specimens of gastric cancer recorded in the histopathology laboratory of the teaching hospital between 1985 to 2004.
  • These were divided into the following groups: Cardia, body and an thrum/pyloric regions respectively.
  • RESULTS: There were a total of 205 gastric cancer histological confirmed, out of 5705 malignant tumours recorded in the same period.
  • The highest frequencies of gastric cancers were located in the anthral and cardia regions which accounted for 79% of all the tumours.
  • Well differentiated adenocarcinoma (intestinal type) was the most frequent histological subtypes 51.2%), this was followed by poorly and diffusely infiltrating carcinoma.
  • The study has also demonstrated H pylori at the background of intestinal type adenocarcinoma which was seen in the body and an thrum.
  • CONCLUSION: The study has shown that gastric cancer is not only common but it occur more males than females.
  • Therefore eradication of H pylori might reduce the prevalence of gastric carcinoma.
  • [MeSH-major] Carcinoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21526638.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


54. Shen H, Newmann AS, Hu Z, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wang X, Wei Q: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep; 2005 Feb;13(2):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China.
  • Studies have suggested that low dietary folate intake is associated with an increased risk of gastric cancer.
  • C677T, A1298C and G1793A) and their haplotypes are associated with the risk of gastric cancer.
  • To test this hypothesis, we genotyped these polymorphisms in a population-based case-control study of 320 incident gastric adenocarcinoma cases and 313 cancer-free controls in a Chinese population.
  • Consistent with our previous observations, the 677TT genotype was associated with a significantly increased risk for gastric cancer (adjusted OR =1.79, 95% CI =1.02-3.15) compared with the 677CC genotype; the association was more evident for gastric cardia adenocarcinoma (adjusted OR =2.60, 95% CI =1.30-5.21).
  • When we used the haplotype analyses and assumed MTHFR 677T, 1298C and 1793A as risk alleles, individuals with 6 variant alleles had a significantly (4.64-fold) increased risk for gastric cardia adenocarcinoma (OR =4.64, 95% CI =1.34-16.01) compared with those having 0-2 variants.
  • These findings suggest that the MTHFR common variants and their haplotypes may play a role in the etiology of gastric cancer, particularly gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Asian Continental Ancestry Group / genetics. Cardia. Case-Control Studies. China / epidemiology. Female. Gene Frequency. Genetic Predisposition to Disease. Haplotypes. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643524.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


55. Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein A, Taylor P: Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer; 2009 Aug 05;9:269
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China.
  • METHODS: 600 esophageal squamous cell carcinoma (ESCC) cases, 598 gastric cardia adenocarcinoma cases, and 316 gastric non-cardia adenocarcinoma cases, and 1514 age-, gender-, and neighborhood-matched controls were asked for FH in first degree relatives and non-blood relatives.
  • FH of gastric cardia cancer was associated with an increased risk of all three cancers.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1991;27(10):1336 [1835609.001]
  • [Cites] Am J Hum Genet. 2000 Jul;67(1):110-9 [10841811.001]
  • [Cites] Jpn J Cancer Res. 1992 Jun;83(6):568-75 [1644660.001]
  • [Cites] Int J Epidemiol. 1992 Oct;21(5):877-82 [1468848.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):195-202 [8318635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):15-8 [8118379.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):775-80 [8206671.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):387-92 [7920205.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):593-600 [7677173.001]
  • [Cites] Jpn J Cancer Res. 1996 Oct;87(10):1025-8 [8957058.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1159-65 [9447394.001]
  • [Cites] Int J Cancer. 1998 May 18;76(4):468-71 [9590119.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):801-5 [9626344.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1997 Oct;18(5):275-8 [9812488.001]
  • [Cites] Am J Epidemiol. 1999 Mar 1;149(5):454-62 [10067905.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3548-54 [15867347.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1390-3 [15941946.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):148-52 [11391635.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):688-94 [11807799.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S1-6 [11821780.001]
  • [Cites] Gut. 2002 Sep;51(3):323-8 [12171951.001]
  • [Cites] J Clin Gastroenterol. 2003 Jan;36(1):30-3 [12488704.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):214-8 [12532434.001]
  • [Cites] Eur J Cancer Prev. 2003 Jun;12(3):183-9 [12771555.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3872-6 [12873975.001]
  • [Cites] Int J Epidemiol. 2003 Aug;32(4):579-83 [12913033.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):240-4 [15019915.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1402-6 [15054463.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1250-7 [15233662.001]
  • [Cites] Sci Sin. 1975 Jan-Feb;18(1):131-48 [1145176.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):2112-6 [4027937.001]
  • [Cites] Chin Med J (Engl). 1985 Oct;98(10):749-52 [3938702.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):755-61 [2714880.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2268-74 [2317814.001]
  • [Cites] Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):584-9 [2119361.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 1990 Dec;70(12):679-81, 46 [1963371.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):565-76 [16083713.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1047-51 [16570268.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):1023-32 [16843873.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1271-83 [17030196.001]
  • [Cites] Fam Cancer. 2006;5(4):343-52 [16724246.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Jun;151(1):17-20 [17690734.001]
  • [Cites] World J Gastroenterol. 2007 Nov 21;13(43):5760-4 [17963305.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1857-63 [18475303.001]
  • [Cites] JAMA. 2008 Jun 4;299(21):2515-23 [18523220.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1429-32 [18567000.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R47 [18507837.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4787-93 [18676749.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1205-13 [11002214.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3476-82 [10589761.001]
  • [Cites] J Natl Cancer Inst. 1992 May 20;84(10):771-6 [1573663.001]
  • (PMID = 19656375.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2729777
  •  go-up   go-down


56. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


57. van Blankenstein M, Looman CW, Siersema PD, Kuipers EJ, Coebergh JW: Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003. Br J Cancer; 2007 Jun 4;96(11):1767-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003.
  • Over the 15-year period 1989-2003, the incidence of oesophagus-cardia adenocarcinoma in the Netherlands rose annually by 2.6% for males and 1.2% for females.
  • This was the net outcome of annual increases in the incidence of adenocarcinoma of the oesophagus (ACO) of 7.2% for males and 3.5% for females and annual declines in the incidence of adenocarcinoma of the gastric cardia (AGC) of more than 1% for both genders.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Clin Ther. 2001 Dec;23(12):1984-98 [11813933.001]
  • [Cites] Bull World Health Organ. 2002;80(1):26-32 [11884970.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1518-20 [11984536.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Int J Obes Relat Metab Disord. 2002 Sep;26(9):1218-24 [12187399.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] Eur J Clin Pharmacol. 2003 Sep;59(5-6):477-82 [12937872.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2487-94 [14602134.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jan;16(1):69-74 [15095855.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Sep;16(9):903-9 [15316416.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55 [15352913.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):880-7 [15476151.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):826-35 [1186274.001]
  • [Cites] Am J Clin Pathol. 1978 Jul;70(1):1-5 [696666.001]
  • [Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]
  • [Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):130-6 [8691857.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1480-2 [9317067.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):353-60 [10365894.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):391-5 [10405839.001]
  • [Cites] Br J Cancer. 1952 Jun;6(2):127-30 [14954081.001]
  • [Cites] Gut. 2005 Jan;54(1):1-3 [15591495.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):766-74 [15784017.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Gut. 2005 Nov;54(11):1527-35 [16227357.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51 [16282279.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Ned Tijdschr Geneeskd. 2005 Dec 10;149(50):2775-82 [16385829.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • (PMID = 17505507.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359916
  •  go-up   go-down


58. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH: Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol; 2005 Mar;3(3):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers.
  • BACKGROUND AND AIMS: Risk factors for subtypes of esophageal and gastric cancer recently have been identified, but their effect on survival is unknown.
  • Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for esophageal and gastric cancer in relation to prediagnostic factors.
  • RESULTS: Relative to distant stage, esophageal adenocarcinoma (EA) patients with localized disease had a decreased risk for death (HR, .22; 95% CI, .15-.31), followed by those with regional spread (HR, .32; 95% CI, .23-.45).
  • Except for other (non-cardia) gastric adenocarcinomas (OGA), higher household income (> or =15,000 US dollars/y vs. <15,000 US dollars/y) was associated with a 33%-38% decrease in risk for death.
  • CONCLUSIONS: Predictors of lengthened esophageal and gastric cancer survival included higher income (except in OGA), overweight (among EA and OGA patients), and female sex (among ES and OGA patients).
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765441.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN05230; United States / NCI NIH HHS / CP / N02-CP40501; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NCI NIH HHS / CA / T32-CA09330; United States / NCI NIH HHS / CA / U01-CA57923; United States / NCI NIH HHS / CA / U01-CA57949; United States / NCI NIH HHS / CA / U01-CA57983
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


59. Wang DC, Wang LD, Zheng S, Fan ZM, Li JL, Feng CW, Zhang YR, Liu B, Gao SS, He X: [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma].
  • OBJECTIVES: To evaluate the serum biomarkers for diagnosis of gastric cardia dysplasia (DYS) and chronic atrophic gastric-carditis (CAG) and to provide a novel screening method for high risk population of gastric-cardia adenocarcinoma (GCA).
  • A set of spectra derived from analysis of serum from 143 symptom-free subjects at high-risk area for GCA, including 63 cases with histologically normal gastric cardia epithelia, 57 of CAG and 23 of DYS, were analyzed by bioinformatics like decision tree classification algorithm.
  • CONCLUSIONS: The gastric cardia lesions of DYS and CAG could be identified by SELDI-TOF-MS technique specifically in symptom-free subjects at high incidence area for GCA.
  • [MeSH-major] Biomarkers, Tumor / blood. Cardia. Gastritis, Atrophic / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194406.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouché O, Conroy T, Pezet D, Triboulet JP, Fédération nationale des centres de lutte contre le cancer (FNCLCC), Fédération hospitalière de France (FHF), Fédération nationale de Cancérologie des CHRU (FNCHRU), Fédération française de cancérologie des CHG (FFCCHG), Centres régionaux de lutte contre le cancer (CRLCC): [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]. Bull Cancer; 2005 Apr;92(4):381-409
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)].
  • [Transliterated title] Recommandations pour la pratique clinique. Standards, Options et Recommandations 2004 pour la prise en charge des patients atteints d'adénocarcinomes de l'estomac, cancers du cardia, autres types histologiques exclus (évaluation des thérapeutiques).
  • OBJECTIVES: To elaborate clinical practice guidelines for patients with stomach adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888395.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 192
  •  go-up   go-down


61. Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P: New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res; 2008 May 1;146(1):149-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New aspects of Helicobacter pylori infection involvement in gastric oncogenesis.
  • Gastric adenocarcinoma not located in the cardia still remains second only to lung cancer as the leading cause of cancer-related mortality worldwide, whereas adenocarcinoma of the cardia and gastroesophageal junction has been rapidly rising over the past two decades.
  • Gastric malignancy can be subdivided into diffuse and intestinal pathologic entities that have different epidemiological and prognostic features.
  • Oncogene overexpression, tumor suppressor loss, and defective DNA mismatch repair is associated with gastric cancer.
  • The latter leads to gastric carcinogenesis through changes related to E-cadherin-catenin complex, which plays a critical role in normal tissue architecture maintenance.
  • Putative trophic factors have also been involved in gastric oncogenesis.
  • This review focuses mainly on Helicobacter pylori infection involved in gastric carcinogenesis through various mechanisms, including repopulation of the stomach with bone marrow-derived stem cells that may facilitate gastric cancer progression, thereby necessitating eradication of this bacterium.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / complications. Stomach Neoplasms / microbiology


62. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol; 2010 Dec 10;28(35):5210-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
  • PURPOSE: Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy.
  • PATIENTS AND METHODS: Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone.
  • RESULTS: This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III.
  • Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Neoadjuvant Therapy / methods. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cardia / pathology. Cardia / surgery. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] JAMA. 2010 May 5;303(17):1729-37 [20442389.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):423-9 [12836016.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1248-52 [7552009.001]
  • [Cites] J Infus Chemother. 1996 Summer;6(3):123-6 [9229322.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2580-5 [17577037.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5062-7 [19770374.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):139-44 [10761793.001]
  • (PMID = 21060024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004099
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10-CA11488-29
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3020693
  •  go-up   go-down


63. Rubenstein JH, Davis J, Marrero JA, Inadomi JM: Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther; 2005 Aug 1;22(3):267-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia.
  • BACKGROUND: Obesity is a risk factor for adenocarcinomas of the oesophagus and gastric cardia.
  • AIM: To estimate the risk of diabetes mellitus on the development of adenocarcinoma of distal oesophagus and gastric cardia beyond that of gastro-oesophageal reflux disease.
  • CONCLUSIONS: Within the limitations of this case-control study, there is no evidence of an association between diabetes and adenocarcinoma of the oesophagus or gastric cardia among US veterans with gastro-oesophageal reflux disease.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Diabetes Mellitus. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091065.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA864000; United States / NIDDK NIH HHS / DK / DK064909
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


64. Lundell LR: Etiology and risk factors for esophageal carcinoma. Dig Dis; 2010;28(4-5):641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trends toward increasing incidence rates were observed for esophageal and gastric cardia adenocarcinoma in Western countries and were associated with trends toward stabilizing or declining incidence rates for esophageal squamous cell carcinoma, suggesting that these tumors might be associated with distinct risk factors.
  • Overweight and obesity have been consistently related to esophageal adenocarcinoma, but not to squamous cell carcinoma.
  • The influence of obesity on esophageal adenocarcinoma and gastric cardia adenocarcinoma may be related to higher incidence of gastroesophageal reflux in obese persons since the risk of gastroesophageal reflux is strongly related to the risk for Barrett's esophagus.
  • Tobacco smoking is a strong risk factor for esophageal squamous cell carcinoma, but is only a weak risk factor for esophageal adenocarcinoma.
  • Alcohol consumption is a strong risk factor for esophageal squamous cell carcinoma, but is not consistently related to esophageal adenocarcinoma.
  • It has been suggested that infection with H. pylori is protective to adenocarcinoma, but might be a risk factor for squamous cell carcinoma, although the role of H. pylori in the etiology of these cancers remains somewhat unclear.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088416.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


65. Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J: Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer; 2006 Jan 16;94(1):136-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.
  • Oesophageal and gastric adenocarcinoma share an unexplained male predominance, which would be explained by the hypothesis that oestrogens are protective in this respect.
  • We carried out a nested case-control study of hormone replacement therapy (HRT) among 299 women with oesophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women, frequency matched by age and calendar year in the General Practitioners Research Database in the United Kingdom.
  • Among 1 619 563 person-years of follow-up, more than 50% reduced risk of gastric adenocarcinoma was found among users of HRT compared to nonusers (odds ratio (OR), 0.48, 95% confidence interval (CI) 0.29-0.79).
  • This inverse association appeared to be stronger for gastric noncardia (OR 0.34, 95% CI 0.14-0.78) and weaker for gastric cardia tumours (OR 0.68, 95% CI 0.23-2.01).
  • There was no association between HRT and oesophageal adenocarcinoma (OR 1.17, 95% CI 0.41-3.32).
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Hormone Replacement Therapy. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] J Chronic Dis. 1980;33(10):595-605 [7410520.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1980 Dec;65(6):1201-7 [7001123.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5181-2 [7139622.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] BMJ. 1991 Mar 30;302(6779):766-8 [2021768.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):66-9 [2044927.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):259-64 [1467771.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Gut. 1993 Dec;34(12):1672-6 [8282253.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] IARC Sci Publ. 1997;(138):325-9 [9353673.001]
  • [Cites] Br J Clin Pharmacol. 1998 May;45(5):419-25 [9643612.001]
  • [Cites] Surg Today. 1998;28(10):1007-14 [9786571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4886-94 [10499548.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):341-5 [11487262.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):319-24 [12073050.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] JAMA. 2002 Aug 21;288(7):872-81 [12186605.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):686-9 [12741446.001]
  • (PMID = 16404367.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361087
  •  go-up   go-down


66. Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU, Engel LS: Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol; 2007 Oct;5(10):1154-1159.e3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers.
  • BACKGROUND & AIMS: The incidence of esophageal and gastric cardia adenocarcinoma has increased in Western countries in recent decades for largely unknown reasons.
  • We investigated whether use of LES-relaxing drugs was related to an increased risk of esophageal and gastric cardia adenocarcinoma, and whether use of NSAIDs was related to a reduced risk of esophageal and gastric cancers.
  • Cases were incident esophageal adenocarcinomas (n = 163) and squamous cell carcinomas (n = 114) and gastric cardia (n = 176) and non-cardia adenocarcinomas (n = 320), diagnosed between 1980-2002 in one health system and between 1993-2002 in the other.
  • RESULTS: Prescription of corticosteroids was associated with a decreased risk of esophageal adenocarcinoma (odds ratio [OR], 0.6; 95% confidence interval [CI], 0.4-0.9), esophageal squamous cell carcinoma (OR, 0.4; 95% CI, 0.2-0.6), and gastric non-cardia carcinoma (OR, 0.4, 95% CI, 0.3-0.6).
  • As a group, LES-relaxing drugs showed little evidence of association with increased risk of any esophageal or gastric cancer.
  • CONCLUSIONS: Corticosteroid and aspirin use were associated with significantly decreased risks of esophageal and gastric cancer.

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):201-13 [15947872.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] J Pharm Pharmacol. 2005 Jul;57(7):851-60 [15969944.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):863-73 [16143126.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(35):3-11 [16287880.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 May;15(5):291-303 [16447304.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] Eff Clin Pract. 2000 Sep-Oct;3(5):213-20 [11185326.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Gastroenterol Clin North Am. 2001 Dec;30(4):1001-10 [11764529.001]
  • [Cites] Epidemiology. 2002 Mar;13(2):240-1 [11880772.001]
  • [Cites] Chest. 2002 Oct;122(4):1256-63 [12377850.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1784-91 [14652240.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Ann Pharmacother. 2004 Jul-Aug;38(7-8):1317-8 [15150379.001]
  • [Cites] Arch Intern Med. 2004 Jul 26;164(14):1482-8 [15277277.001]
  • [Cites] Cancer Causes Control. 1994 Nov;5(6):573-8 [7827245.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56 [9752982.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • (PMID = 17644046.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA140754; United States / NCI NIH HHS / CA / U19 CA079689; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CA / U19 CA79689
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antidepressive Agents; 0 / Histamine H1 Antagonists
  • [Other-IDs] NLM/ NIHMS32453; NLM/ PMC2140196
  •  go-up   go-down


67. Xu DK, Zhao P, Wang CF, Shao YF, Lin HW, Tian YT: [Clinicopathological characteristics and prognosis of remnant stomach cancer--report of 45 cases]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):852-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristics and prognosis of remnant stomach cancer--report of 45 cases].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognostic factors of remnant stomach cancer.
  • METHODS: The clinicopathological and prognosis data of 45 patients with remnant stomach cancer were retrospectively analyzed.
  • RESULTS: The remnant stomach cancer are likely to develop in males with a ratio of male to female: 44:1.
  • The interval from the initial operation to the diagnosis of remnant stomach cancer was 5 to 42 years with an average of 23 years.
  • Of these 45 patients, 28 had lesion at anastomotic site, 9 in the gastric cardia and 8 in other locations; 19 had radical resection, 16 palliative resection and 10 exploration alone except one who had an anastomosis of remnant stomach with the jejunum.
  • The histology types included: 1 un-differentiated adenocarcinoma, 36 poorly-differentiated adenocarcinoma, 7 moderately-differentiated adenocarcinoma and 1 well-differentiated adenocarcinoma.
  • CONCLUSION: Remnant stomach cancer prevalently occurs in the male usually 10 years after Birroth II gastrectomy.
  • Poorly-differentiated adenocarcinoma is found to be the prevalent histological type of advanced remnant stomach cancer.
  • The prognosis of remnant stomach cancer is correlated with pTNM stage and whether having been treated with complete resection or not.
  • Patients with early remnant stomach cancer may survive for a long time if radical resection can be done.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Gastric Stump / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416009.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Bhurgri Y, Pervez S, Kayani N, Haider S, Ahmed R, Usman A, Bashir I, Bhurgri A, Hasan SH, Zaidi SM: Rising incidence of gastric malignancies in Karachi, 1995- 2002. Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):41-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising incidence of gastric malignancies in Karachi, 1995- 2002.
  • INTRODUCTION: South Asia is an enigma for gastric cancer, a low risk region with a contradictory high prevalence for Helicobacter pylori.
  • PATIENTS AND METHODS: To examine the demographics, pathology and trends of gastric cancer in Pakistan, epidemiological data of 335 gastric malignancies, registered at Karachi Cancer Registry (KCR) for Karachi South (KS), during 1st January 1995 to 31st December 2002 were reviewed.
  • RESULTS: Ninety six cases of gastric cancers were registered in the 1995-7 period, 61 in males and 35 in females.
  • In the 1998-02 period 239 cases of gastric cancer were registered, 156 cases in males and 83 in females.
  • The majority of the cases presented as poorly or moderately differentiated distal (non-cardia) cancers with a regional spread.
  • CONCLUSION: Gastric cancers in Karachi fall into the prototype of a low risk developing country pattern.
  • Larger pathology-based studies are required to comment on the precise morphological sub-types of gastric adenocarcinoma.
  • Etiological studies focused on different strains of H. pylori are required to address the gastric cancer enigma, whilst examining possible protective environmental or genetic factors.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469622.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


69. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF Jr, El-Omar EM: A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology; 2007 Mar;132(3):905-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors.
  • The TLR4+896A>G polymorphism linked with impaired reactivity to bacterial lipopolysaccharide may play a role in gastric carcinogenesis.
  • METHODS: We assessed associations with premalignant gastric changes in 149 relatives of gastric cancer patients, including 45 with hypochlorhydria and gastric atrophy.
  • We also genotyped 2 independent Caucasian population-based case-control studies of upper gastrointestinal tract cancer, initially in 312 noncardia gastric carcinoma cases and 419 controls and then in 184 noncardia gastric carcinomas, 123 cardia carcinomas, 159 esophageal cancers, and 211 frequency-matched controls.
  • RESULTS: TLR4+896G carriers had an 11-fold (95% confidence interval [CI], 2.5-48) increased odds ratio (OR) for hypochlorhydria; the polymorphism was unassociated with gastric acid output in the absence of H pylori infection.
  • Carriers also had significantly more severe gastric atrophy and inflammation.
  • Seventeen percent of gastric carcinoma patients in the initial study and 15% of the noncardia gastric carcinoma patients in the replication study had 1 or 2 TLR4 variant alleles vs 8% of both control populations (combined OR = 2.3; 95% CI = 1.6-3.4).
  • In contrast, prevalence of TLR4+896G was not significantly increased in esophageal squamous cell (2%, OR = 0.2) or adenocarcinoma (9%, OR = 1.4) or gastric cardia carcinoma (11%, OR = 1.4).
  • CONCLUSIONS: Our data suggest that the TLR4+896A>G polymorphism is a risk factor for noncardia gastric carcinoma and its precursors.
  • [MeSH-major] Carcinoma / genetics. Helicobacter Infections / microbiology. Helicobacter pylori. Polymorphism, Genetic. Precancerous Conditions / genetics. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324405.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CZB/4/485; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  •  go-up   go-down


70. Schuhmacher C, Novotny A, Ott K, Feith M, Siewert JR: [Lymphadenectomy with tumors of the upper gastrointestinal tract]. Chirurg; 2007 Mar;78(3):203-6, 208-12, 214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Locally advanced Barrett carcinoma is also an indication for classic two-field lymphadenectomy together with abdominothoracic oesophagectomy and creation of a stomach tube with intrathoracic anastomosis.
  • Adenocarcinoma of the cardia and subcardial gastric cancer including the cardia both require lymphadenectomy analogous to that performed in gastric cancer, with special attention paid to the retroperitoneal lymphatic drainage towards the left kidney pedicle.
  • For therapy of gastric cancer, a systematic D2 lymphadenectomy should always be performed.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Lymph Node Excision / methods. Precancerous Conditions / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Cardia / pathology. Cardia / surgery. Esophagectomy / methods. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging. Prognosis. Thoracic Cavity / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Oct;15(4):751-64 [17030271.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Br J Surg. 1998 Jun;85(6):840-4 [9667720.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1576-84 [16317484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):303-8 [15028313.001]
  • [Cites] Chirurg. 2006 Dec;77(12):1095-103 [17119884.001]
  • [Cites] World J Surg. 2005 Jun;29(6):700-7 [16078126.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):905-8 [2804584.001]
  • [Cites] Surg Technol Int. 2006;15:32-6 [17029158.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] Br J Surg. 2002 May;89(5):604-8 [11972551.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] World J Surg. 2006 Feb;30(2):191-8 [16425071.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):1015-20 [15239237.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):743-52 [11088069.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1441-9 [16871357.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Chirurg. 2005 Jun;76(6):588-94 [15875146.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):483-90 [15024309.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 17333037.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Lagergren J, Ye W, Lagergren P, Lu Y: The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology; 2010 Apr;138(4):1297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of esophageal adenocarcinoma after antireflux surgery.
  • BACKGROUND & AIMS: The question of a possible preventive effect of antireflux surgery on the development of esophageal or cardia adenocarcinoma remains unsettled.
  • We aimed to clarify whether antireflux surgery prevents later development of esophageal adenocarcinoma.
  • Overall risk of esophageal adenocarcinoma (n = 39) was increased 12-fold (SIR, 12.3; 95% confidence interval [CI], 8.7-16.8).
  • For the corresponding overall risk of cardia adenocarcinoma (n = 21) the SIR was 4.4 (95% CI, 2.7-6.7), without any major decrease in risk with time (P = .20); the SIR was 3.1 (95% CI, 0.6-9.1) after at least 15 years of follow-up evaluation.
  • No association between antireflux surgery and gastric adenocarcinoma or esophageal squamous cell carcinoma was identified.
  • CONCLUSIONS: Antireflux surgery cannot be considered to prevent the development of esophageal or cardia adenocarcinoma among persons with reflux.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / surgery
  • [MeSH-minor] Cardia. Cohort Studies. Female. Humans. Male. Middle Aged. Risk. Stomach Neoplasms / prevention & control


72. Lindblad M, Ye W, Lindgren A, Lagergren J: Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg; 2006 Apr;243(4):479-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates.
  • OBJECTIVE: To evaluate the diagnostic accuracy of esophageal and cardia adenocarcinoma in the Swedish Cancer Register.
  • SUMMARY BACKGROUND DATA: Based on cancer registers, a rising incidence of esophageal and cardia adenocarcinoma has been reported in several populations, but possible influence of differences in tumor classification has not been evaluated.
  • METHODS: In a nationwide study in 1995 through 1997, all Swedish patients, born in Sweden and younger than 80 years with esophageal or cardia adenocarcinoma and half of all patients with esophageal squamous cell carcinoma, were prospectively, uniformly, and thoroughly classified.
  • RESULTS: The overall completeness of the Cancer Register was high (98.3%), whereas the site-specific completeness of the Register was 63% for esophageal adenocarcinoma, 74% for cardia adenocarcinoma, and 91% for esophageal squamous cell carcinoma.
  • The incidence of esophageal adenocarcinomas was 16% higher in the study classification compared with that of the Register during the study period, whereas the incidence of cardia adenocarcinoma was 2% lower in the study classification.
  • CONCLUSIONS: There is a diagnostic mismatch between esophageal and cardia adenocarcinoma in the clinical setting and, therefore, also in Cancer Registers.
  • The increasing incidence rate of esophageal adenocarcinoma in Sweden is unlikely to be explained by such differences in tumor classification, however.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / classification. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg. 2001 Oct;167(10):748-57 [11775726.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Chirurg. 1987 Jan;58(1):25-32 [3829805.001]
  • [Cites] Ugeskr Laeger. 1987 Jul 6;149(28):1904-9 [3433407.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):374-7 [8472157.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1082-6 [11099062.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):786-90 [10328109.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):834-42 [10360663.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • (PMID = 16552198.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448962
  •  go-up   go-down


73. Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR: Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol; 2006 Sep 15;94(4):307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction.
  • BACKGROUND: Adenocarcinoma of the esophago-gastric junction (EGJ) potentially spreads to abdominal and mediastinal lymph nodes.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophagogastric Junction. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Barrett Esophagus / pathology. Cardia. Esophageal Neoplasms / mortality. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Risk. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16917878.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer; 2007;10(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
  • BACKGROUND: MK-1, the target molecule of FU-MK-1, is encoded by the GA733-2 gene, which is currently being used as a target in clinical trials for gastric, intestinal and biliary cancer treatment with monoclonal antibodies.
  • METHODS: The expression of p53 protein and MK-1 antigen was investigated in specimens from 42 patients with gastric carcinoma.
  • MK-1 expression was more frequent in cardia tumors (71%), in large (>3 cm) tumors (60%-64%), and in specimens from patients with more than five metastatic lymph nodes (69%).
  • Of these 20 patients, 15 (52%) had tubular adenocarcinoma (TA) and 5 (38%) had signet ring cell carcinoma. p53 expression was more frequent in the tumors of male patients (55% vs 27%); in poorly differentiated TAs (60% vs 47% in well-to-moderately differentiated TAs); in smaller tumors (< or = 3 cm, 72% vs 43%-50% in larger tumors); in patients with a prominent inflammatory response (61% vs 21%; P < 0.02); and in patients with lymphatic vessel invasion (77% vs 34%; P < 0.02).
  • Most patients with p53- and MK-1-positive gastric carcinomas and those more than five metastatic lymph nodes had a poor prognosis.
  • CONCLUSION: The study found that the expression of both p53 and MK-1 was frequent in aggressive gastric carcinomas; however, extensive lymph node involvement (more than five nodes) was the only significant factor related to overall survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(4):343-7 [8205349.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):211-6 [16616808.001]
  • [Cites] Arch Pathol Lab Med. 1977 Nov;101(11):568-71 [334106.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Br J Cancer. 1994 May;69(5):943-6 [8180028.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2649-55 [7538044.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):653-61 [8398688.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):584-9 [8099338.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):231-8 [10761711.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Virchows Arch. 1994;424(2):187-93 [8180781.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):769-76 [12014649.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1247-53 [7977948.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2001-7 [12174877.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3952-6 [6744310.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):174-86 [8424417.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2439-47 [7680948.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2443-50 [1933781.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Histopathology. 2004 Apr;44(4):323-31 [15049897.001]
  • (PMID = 17577621.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Palli D, Masala G, Del Giudice G, Plebani M, Basso D, Berti D, Numans ME, Ceroti M, Peeters PH, Bueno de Mesquita HB, Buchner FL, Clavel-Chapelon F, Boutron-Ruault MC, Krogh V, Saieva C, Vineis P, Panico S, Tumino R, Nyrén O, Simán H, Berglund G, Hallmans G, Sanchez MJ, Larrãnaga N, Barricarte A, Navarro C, Quiros JR, Key T, Allen N, Bingham S, Khaw KT, Boeing H, Weikert C, Linseisen J, Nagel G, Overvad K, Thomsen RW, Tjonneland A, Olsen A, Trichoupoulou A, Trichopoulos D, Arvaniti A, Pera G, Kaaks R, Jenab M, Ferrari P, Nesi G, Carneiro F, Riboli E, Gonzalez CA: CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer; 2007 Feb 15;120(4):859-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study.
  • Helicobacter pylori (H. pylori), atrophic gastritis, dietary and life-style factors have been associated with gastric cancer (GC).
  • According to site, the risk of noncardia GC associated with CagA seropositivity showed a further increase (OR 6.5; 95% CI 3.3-12.6); on the other hand, a ten-fold increased risk of cardia GC was associated with SCAG (OR 11.0; 95% CI 3.0-40.9).
  • This association was limited to distal GC, while serologically defined SCAG was strongly associated with cardia GC, thus suggesting a divergent risk pattern for these 2 sites.
  • [MeSH-major] Adenocarcinoma / microbiology. Antibodies, Bacterial / blood. Antigens, Bacterial / immunology. Bacterial Proteins / immunology. Helicobacter Infections / microbiology. Helicobacter pylori / isolation & purification. Stomach Neoplasms / microbiology
  • [MeSH-minor] Cardia / microbiology. Cardia / pathology. Case-Control Studies. Cohort Studies. Humans. International Agencies. Male. Middle Aged. Prevalence. Prospective Studies. Risk Assessment. Risk Factors. Seroepidemiologic Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Cancer. 2007 Aug 15;121(4):928. E Numans, Mattijs [corrected to Numans, Mattijs E]
  • (PMID = 17131317.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527; United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


76. Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, Park DJ, Lee HS, Jung HC, Song IS: Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol; 2010 Mar;25(3):512-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography.
  • BACKGROUND AND AIM: The aim of this study was to determine the accuracy of endoscopic ultrasonography (EUS) and multidetector-row computed tomography (MDCT) for the locoregional staging of gastric cancer.
  • EUS and computed tomography (CT) are valuable tools for the preoperative evaluation of gastric cancer.
  • The performance of EUS and MDCT for large lesions and lesions at the cardia and angle had significantly lower accuracy than that of other groups.
  • For EUS, the early gastric cancer lesions with ulcerative changes had significantly lower accuracy than those without ulcerative changes.
  • CONCLUSIONS: For the preoperative assessment of individual T and N staging in patients with gastric cancer, the accuracy of MDCT was close to that of EUS.
  • Both EUS and MDCT are useful complementary modalities for the locoregional staging of gastric cancer.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370729.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


77. Lagergren J, Jansson C, Viklund P: Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study. Eur J Cancer; 2006 Sep;42(14):2359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study.
  • The aim of this study was to test the hypothesis that chewing gum is associated with risk of oesophageal and cardia adenocarcinoma.
  • In all, 189 and 262 patients with oesophageal and cardia adenocarcinoma, respectively, and 820 population-based control subjects were interviewed.
  • Regular users of chewing gum (P3 times/week for P6 months) were not at increased risk of oesophageal adenocarcinoma (OR 1.0, 95% CI 0.6-2.2), and no duration-response relation was observed (P = 0.38).
  • No association between regular gum chewing and cardia adenocarcinoma was found (OR 1.0, 95% CI 0.6-1.7), irrespective of duration of use (P = 0.56).
  • In conclusion, with regard to risk of oesophageal or cardia adenocarcinoma, gum chewing seems harmless.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Chewing Gum / adverse effects. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890425.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chewing Gum
  •  go-up   go-down


78. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE: Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut; 2009 Jan;58(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females.
  • BACKGROUND AND AIMS: Upper gastrointestinal adenocarcinomas show an unexplained male predominance that is more apparent in oesophagus than stomach and in intestinal than diffuse histological subtype.
  • METHOD AND MATERIALS: Of 3270 gastric and oesophageal cancers recorded in the West of Scotland Cancer Registry, 1998-2002, 812 were randomly selected for detailed analysis.
  • The Lauren histological subtype of adenocarcinoma was determined by reviewing 1204 original reports and 3241 biopsies.
  • RESULTS: Analysis included 405 non-cardia cancers, 173 cardia cancers and 209 oesophageal adenocarcinomas.
  • The M/F ratios for oesophageal, cardia and non-cardia gastric cancer were 3.5, 2.0 and 1.6, respectively.
  • CONCLUSION: Male predominance of upper gastrointestinal adenocarcinoma is related to the intestinal histological subtype rather than tumour location and is due to marked delayed development of this subtype in females prior to 50-60 years of age.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology


79. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol; 2005 Jun 1;90(3):139-46; discussion 146
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.
  • A topographic-anatomic subclassification of adenocarcinomas of the esophago-gastric junction (AEG) in distal esophageal adenocarcinoma (AEG Type I), true carcinoma of the cardia (AEG Type II), and subcardial gastric cancer (AEG Type III) was introduced in 1987 and is now increasingly accepted and used worldwide.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms / classification. Esophagogastric Junction. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15895452.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


80. Lee WA: Gastric extremely well differentiated adenocarcinoma of gastric phenotype: as a gastric counterpart of adenoma malignum of the uterine cervix. World J Surg Oncol; 2005 May 23;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric extremely well differentiated adenocarcinoma of gastric phenotype: as a gastric counterpart of adenoma malignum of the uterine cervix.
  • BACKGROUND: Most of gastric adenocarcinoma can be simply diagnosed by microscopic examination of biopsy specimen.
  • CASE PRESENTATION: A 67-year-old male presented with a gastric mass incidentally found on the abdominal computed tomography (CT) for routine medical examination.
  • Gastric endoscopic examination revealed a huge fungating mass at the cardia and mucosal biopsy was performed.
  • The resected stomach revealed a huge fungating tumor at the cardia.
  • Microscopically the tumor was sharply demarcated from surrounding mucosa and composed of very well formed glandular structures without significant cellular atypia, which invaded into the whole layer of the gastric wall.
  • CONCLUSION: The clinicopathologic profiles of gastric extremely well differentiated adenocarcinoma of gastric phenotype include cardiac location, fungating gross type, very similar histology to foveolar epithelial hyperplasia, foveolar mucin phenotype, lack of p53 overexpressoin and high proliferative index.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1031-5 [11014567.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):854-60 [15533229.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):683-92 [12428787.001]
  • (PMID = 15907218.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1180859
  •  go-up   go-down


81. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T: Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus; 2007;20(1):36-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?
  • Adenocarcinoma of the distal esophagus and gastroesophageal junction are believed to arise in Barrett's esophagus with intestinal metaplasia.
  • Whether adenocarcinoma can arise in columnar lined esophagus without intestinal metaplasia is in doubt.
  • Whether adenocarcinoma of the gastric cardia arises in intestinal metaplasia of the gastric cardia is also in doubt.
  • We aim to evaluate the relationship of size and stage of adenocarcinoma of the distal esophagus, gastroesophageal junction and gastric cardia to intestinal metaplasia and other types of columnar epithelium.
  • Residual intestinal metaplasia was present in 48 (65%) tumors, including 33/38 (87%) distal esophageal, 10/25 (45%) junctional and 5/11 (45%) gastric cardia tumors.
  • These data strongly support the contention that adenocarcinomas of this region, including those in the gastric cardia, arise in intestinal metaplastic epithelium.


82. Wen S, Moss SF: Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett; 2009 Sep 8;282(1):1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori virulence factors in gastric carcinogenesis.
  • Helicobacter pylori infection is the most important risk factor in the development of non-cardia gastric adenocarcinoma; host genetic variability and dietary co-factors also modulate risk.
  • Improved understanding of the pathogenesis of H. pylori-associated gastric cancer may improve risk stratification for prevention and therapy.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 May 24;26(24):3462-72 [17160020.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2896-909 [17768234.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5433-40 [17911630.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):862-6 [17943123.001]
  • [Cites] J Cell Physiol. 2008 Mar;214(3):582-7 [17786942.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Cell Host Microbe. 2008 Jan 17;3(1):20-9 [18191791.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):379-87 [18199531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1003-8 [18192401.001]
  • [Cites] Cell Microbiol. 2008 Mar;10(3):781-94 [18005242.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):510-4 [18341483.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1267; author reply 1268 [18395110.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(4):971-80 [11929545.001]
  • [Cites] Science. 2002 Jul 26;297(5581):573-8 [12142529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] Cell Microbiol. 2003 Jan;5(1):25-40 [12542468.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):951-7 [12615708.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Science. 2003 May 30;300(5624):1430-4 [12775840.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1099-102 [12934009.001]
  • [Cites] Cell Microbiol. 2004 Feb;6(2):167-74 [14706102.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2106-11 [14762173.001]
  • [Cites] J Infect Dis. 2004 Mar 1;189(5):820-7 [14976598.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7727-32 [15128946.001]
  • [Cites] Science. 2004 Jul 23;305(5683):519-22 [15273394.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1166-74 [15489856.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10570-5 [1587837.001]
  • [Cites] Science. 1993 Dec 17;262(5141):1892-5 [8018146.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] Trends Microbiol. 1994 Jul;2(7):221-8 [8081648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9720-4 [7937879.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] J Clin Pathol. 1995 Oct;48(10):967-9 [8537502.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):242-9 [8657240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14648-53 [8962108.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):92-9 [8978347.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1344-7 [9163441.001]
  • [Cites] Nature. 1997 Aug 7;388(6642):539-47 [9252185.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):135-40 [9419220.001]
  • [Cites] Science. 1998 Jan 16;279(5349):373-7 [9430586.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2258-63 [9666002.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10212-7 [9707626.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):813-20 [9710450.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):176-80 [9923682.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):259-68 [9922305.001]
  • [Cites] Science. 1999 May 21;284(5418):1328-33 [10334982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16923-8 [15557006.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):320-32 [15759043.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):15390-7 [15689619.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):833-48 [15825067.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):23130-7 [15831497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9300-5 [15972330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9661-6 [15980153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Nov;21(6):653-9 [16220040.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 [16258069.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Infect Immun. 2006 Jan;74(1):273-81 [16368981.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1181-90 [16618412.001]
  • [Cites] Infect Immun. 2006 Jul;74(7):4375-8 [16790815.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):633-49 [16997150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1920-8 [17035400.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e110 [17121461.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):915-8 [17287725.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1309-19 [17408661.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):115-28 [10620610.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Infect Immun. 2000 Jun;68(6):3754-7 [10816542.001]
  • [Cites] Int J Cancer. 2000 Aug 1;87(3):322-7 [10897035.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1601-10 [11104802.001]
  • [Cites] J Clin Invest. 2001 Mar;107(5):611-20 [11238562.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1903-9 [11280745.001]
  • [Cites] J Clin Microbiol. 2001 Jul;39(7):2463-5 [11427555.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):823-9 [11606496.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6499-508 [11673417.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):3033-41 [11884476.001]
  • [Cites] Mol Microbiol. 2001 Dec;42(5):1337-48 [11886563.001]
  • (PMID = 19111390.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125126-01A1; United States / NCI NIH HHS / CA / R21 CA125126-01A1; United States / NCI NIH HHS / CA / R01 CA111533-03; United States / NCI NIH HHS / CA / R21 CA125126; United States / NCI NIH HHS / CA / CA111533-03; United States / NCI NIH HHS / CA / R01 CA111533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori; 0 / Virulence Factors; 0 / cagA protein, Helicobacter pylori
  • [Number-of-references] 96
  • [Other-IDs] NLM/ NIHMS133225; NLM/ PMC2746929
  •  go-up   go-down


83. Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol; 2009 Feb;16(2):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.
  • The surgical strategy for adenocarcinoma of the esophagogastric junction is still controversial.
  • The aim of this study was to evaluate surgical results of the abdominal-transhiatal approach for 100 consecutively operated type II and III cardia adenocarcinoma, to clarify clinicopathological differences between these tumors, and to define prognostic factors.
  • A prospectively maintained database identified 100 consecutively operated patients with Siewert type II and III cardia adenocarcinoma.
  • True carcinoma of the cardia may be a distinct clinical entity with a more aggressive natural history than subcardial gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia / pathology. Cardia / surgery. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2074-5; author reply 2076 [19365623.001]
  • (PMID = 19050964.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Hanazono K, Natsugoe S, Stein HJ, Aikou T, Hoefler H, Siewert JR: Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression. Oncol Rep; 2006 Apr;15(4):821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression.
  • This study investigated the distribution of p53 mutations within both esophageal and gastric adenocarcinomas.
  • The patients included 8 cases of adenocarcinoma from the cardia (esophagogastric junction) and 9 cases of gastric carcinoma.
  • DHPLC demonstrated that 37.5% (3/8) of esophageal carcinomas and 44.4% (4/9) of gastric carcinomas have p53 mutations.
  • [MeSH-major] Mutation. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525665.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


85. Ding GC, Ren JL, Chang FB, Li JL, Yuan L, Song X, Zhou SL, Guo T, Fan ZM, Zeng Y, Wang LD: Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers. World J Gastroenterol; 2010 Dec 14;16(46):5901-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers.
  • AIM: To investigate the relationship between human papillomavirus (HPV) infection and concurrent esophagus and gastric cardia cancer from the same patient (CC) and examine the significance of P16(INK4A) protein expression.
  • RESULTS: Among the CC specimens, HPV16-DNA was found in eight cases of esophageal squamous cell carcinoma (ESCC) and five cases of gastric cardia adenocarcinoma (GCA), respectively (47% vs 29%), and two of both ESCC and GCA.
  • P16(INK4A) may be a screening index in the HPV-associated carcinoma of gastric cardia.
  • [MeSH-major] Cardia / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / genetics. Esophageal Neoplasms / virology. Human papillomavirus 16 / genetics. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):874-8 [10842204.001]
  • [Cites] Dis Esophagus. 2004;17(1):10-26 [15209736.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):929-34 [11375901.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):16-21 [12508343.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1170-3 [12800217.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2003 Nov 10;83(21):1910-4 [14642078.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Diagn Histopathol. 1982 Oct-Dec;5(4):291-6 [6188592.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1554-9 [17453003.001]
  • [Cites] Mol Carcinog. 2008 Feb;47(2):100-4 [17918207.001]
  • [Cites] Magy Seb. 2008 Aug;61(4):225-9 [18799406.001]
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Aug;22(4):251-3 [19105334.001]
  • [Cites] J BUON. 2009 Jul-Sep;14(3):495-9 [19810144.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1137-9 [20332262.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Nov;126(11):655-60 [11079730.001]
  • (PMID = 21155014.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC3001984
  •  go-up   go-down


86. Gulmann C, Lantuejoul S, Grace A, Leader M, Patchett S, Kay E: Telomerase activity in proximal and distal gastric neoplastic and preneoplastic lesions using immunohistochemical detection of hTERT. Dig Liver Dis; 2005 Jun;37(6):439-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in proximal and distal gastric neoplastic and preneoplastic lesions using immunohistochemical detection of hTERT.
  • BACKGROUND: The incidence of distal (corpus and antrum) gastric adenocarcinoma is decreasing with a simultaneous increase in incidence of proximal (cardia) adenocarcinoma.
  • Intestinal metaplasia may have a lower malignant potential in the proximal stomach but regardless of the locations, its specificity as a predictor of carcinoma is low.
  • AIMS: The aim of this study was to establish whether human telomerase reverse transcriptase expression differs at various points in proximal versus distal gastric carcinogenesis and to test the utility of human telomerase reverse transcriptase expression as a marker of cancer risk in intestinal metaplasia.
  • MATERIAL AND METHODS: Wax-embedded tissue from proximal and distal stomach including normal mucosa (n=86), intestinal metaplasia (n=83) and carcinoma (n=101) were used and slides were immunostained for human telomerase reverse transcriptase and pRb and scored semi-quantitatively.
  • RESULTS: The results showed that in both proximal and distal stomach, human telomerase reverse transcriptase expression rates increased from normal mucosa to cancer.
  • CONCLUSIONS: In conclusion, telomerase activity appears to be an early event in both proximal and distal gastric carcinogenesis and human telomerase reverse transcriptase is expressed in intestinal metaplasia.
  • [MeSH-major] Carcinoma / metabolism. DNA-Binding Proteins / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893283.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Retinoblastoma Protein; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


87. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia]. Chin J Cancer; 2010 Jan;29(1):94-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia].
  • BACKGROUND AND OBJECTIVE: The incidence of adenocarcinoma of the cardia has recently increased.
  • This study compared the clinicopathology and prognosis of patients with gastric cardia adenocarcinoma in different periods between 1984 and 2003.
  • METHODS: A total of 589 patients with pathologically confirmed gastric cardia adenocarcinoma hospitalized in Sun Yat-sen University Cancer Center between 1984 and 2003 were divided into 5-year groups.
  • CONCLUSIONS: During the past 20 years, associated with the upward-trending incidence of gastric cardia adenocarcinoma, the admission rate at our hospital of patients with the tumor increased.
  • [MeSH-major] Adenocarcinoma. Cardia / pathology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038318.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Buchs NC, Bucher P, Pugin F, Hagen ME, Morel P: Robot-assisted oncologic resection for large gastric gastrointestinal stromal tumor: a preliminary case series. J Laparoendosc Adv Surg Tech A; 2010 Jun;20(5):411-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted oncologic resection for large gastric gastrointestinal stromal tumor: a preliminary case series.
  • BACKGROUND: Laparoscopic resection of gastric gastrointestinal stromal tumor (GIST) has been shown as feasible and safe in terms of oncologic results.
  • The robotic approach may, by its characteristics, enable the surgeon to perform atypical gastrectomies in an unfavorable location (i.e., close to pylorus or cardia).
  • Its use in oncologic gastric surgery has been poorly defined and has never been reported for GIST.
  • MATERIALS AND METHODS: All patients who underwent robotic-assisted gastric resection for GIST at a single institution from 2006 to 2009 were prospectively followed-up.
  • One patient had a conversion to open surgery because of a suspicion of diffuse adenocarcinoma on fresh frozen section and necessitated a total gastrectomy with a radical lymph node dissection.
  • CONCLUSIONS: The da Vinci robot (Intuitive Surgical, Inc., Sunnyvale, CA) is a valuable instrument for oncologically safe resection with esogastric or duodenogastric junction preservation for an unfavorably located gastric GIST.
  • Moreover, the three-dimensional, high-definition vision, instrument mobility, and ease of performing a difficult suturing enable a safe, large atypical gastrectomy, close to the pylorus or cardia.
  • [MeSH-major] Gastrectomy / instrumentation. Gastrointestinal Stromal Tumors / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459328.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


90. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol; 2009 Feb 20;27(6):851-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.
  • PURPOSE: Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma.
  • PATIENTS AND METHODS: Patients with locally advanced (uT3-4NXM0) adenocarcinoma of the lower esophagus or gastric cardia were randomly allocated to one of two treatment groups: induction chemotherapy (15 weeks) followed by surgery (arm A); or chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 20;27(6):836-7 [19139425.001]
  • (PMID = 19139439.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


91. Rutegård M, Shore R, Lu Y, Lagergren P, Lindblad M: Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer; 2010 Apr;46(6):1093-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006.
  • BACKGROUND: Oesophageal and gastric adenocarcinoma share a male predominance not seen for other adenocarcinomas of the gastrointestinal tract.
  • METHODS: The Swedish Cancer Register was used to collect primary oesophageal, gastric cardia, non-cardia gastric, colonic and pancreatic adenocarcinoma cases aged 25-84, during the study period of 1970-2006.
  • RESULTS: The sex ratio for oesophageal adenocarcinoma ranged from approximately 10:1 to 4:1, presenting a seemingly consistent decline with age.
  • The sex ratio for non-cardia gastric adenocarcinoma, however, increased with age to reach 2:1 at a point one to two decades after menopause, where the ratio levelled off and eventually declined.
  • There was no discernible time period effect concerning any type of adenocarcinoma.
  • The ratios for gastric cardia, colonic and pancreatic adenocarcinoma were stable with age.
  • CONCLUSION: This study indicates separate patterns of age-dependency of the sex difference in oesophageal and non-cardia gastric adenocarcinoma incidence.
  • The non-cardia gastric adenocarcinoma pattern might be due to a protective effect during premenopausal years for the female population, while the seemingly steady decline in sex ratio in oesophageal adenocarcinoma indicates a mechanism independent of menopause.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology. Esophageal Neoplasms / epidemiology. Pancreatic Neoplasms / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cardia. Female. Humans. Incidence. Male. Middle Aged. Sex Distribution. Sweden / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20188539.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Cheng Y, Zhang J, Li Y, Wang Y, Gong J: Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection. BMC Cancer; 2007;7:191
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection.
  • BACKGROUND: The incidence of gastric cardiac adenocarcinoma (GCA) has been increasing in the past two decades in China, but the molecular changes relating to carcinogenesis have not been well characterised.
  • METHODS: In this study, we used a comparative proteomic approach to analyse the malignant and nonmalignant gastric cardia epithelial cells isolated by navigated laser capture microdissection (LCM) from paired surgical specimens of human GCA.
  • [MeSH-major] Adenocarcinoma / metabolism. Cardia / metabolism. Proteome / analysis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2003 May;3(5):610-5 [12748941.001]
  • [Cites] Adv Clin Chem. 2006;42:167-216 [17131627.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):505-9 [12923326.001]
  • [Cites] Duodecim. 1996;112(24):2383-8 [10605239.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5958-65 [10681589.001]
  • [Cites] Electrophoresis. 2000 Jun;21(11):2235-42 [10892734.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Prog Biophys Mol Biol. 2000;73(2-4):91-134 [10958928.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):998-1001 [11020863.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):666-72 [11041055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12601-6 [11050178.001]
  • [Cites] EXS. 2000;(90):462-74 [11268530.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1339-45 [11396210.001]
  • [Cites] Mol Pathol. 2001 Aug;54(4):253-8 [11477141.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):815-22 [11891180.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] Electrophoresis. 2002 Aug;23(15):2513-24 [12210210.001]
  • [Cites] Electrophoresis. 2003 Jan;24(1-2):296-302 [12652601.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3641-4 [14506152.001]
  • [Cites] Cell Cycle. 2003 Nov-Dec;2(6):579-84 [14512773.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):970-9 [14578131.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1988-2001 [14625861.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):335-45 [14973377.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):111-8 [15145526.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5595-605 [15169918.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):363-85 [2017217.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):272-9 [7705958.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Trends Genet. 1998 Jul;14(7):272-6 [9676529.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9018-26 [15604267.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1160-6 [15759317.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):585-91 [15900315.001]
  • [Cites] J Cell Sci. 2005 Jul 15;118(Pt 14):3173-83 [16014382.001]
  • [Cites] Cell Stress Chaperones. 2005 Summer;10(2):86-103 [16038406.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3205-13 [16003825.001]
  • [Cites] Proteomics. 2006 Jan;6(2):538-46 [16342242.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Ai Zheng. 2006 Feb;25(2):194-9 [16480585.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1998-2002 [16287084.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):840-7 [16344274.001]
  • [Cites] Respirology. 2006 May;11(3):269-75 [16635084.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6080-6 [16778180.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1864-9 [16983479.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):131-43 [12871776.001]
  • (PMID = 17927838.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteome
  • [Other-IDs] NLM/ PMC2151079
  •  go-up   go-down


93. Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS: Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol; 2009 Mar;24(3):354-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis.
  • There is conflicting data regarding the clinicopathological significance of the risk factors associated with Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC).
  • EBVaGC developed most often in the cardia and body, and it generally showed the diffuse histological type.
  • The clinicopathological and molecular characteristics of EBVaGC are quite different from those of conventional gastric adenocarcinoma.
  • [MeSH-major] Carcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335785.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 75
  •  go-up   go-down


94. Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, Tsujii S, Onishi S, Kobayashi M, Hanazaki K: Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg; 2008 Feb;206(2):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach?
  • BACKGROUND: Although the incidence of gastric cardia cancer is considerably less than more distal gastric cancer, the rate of occurrence is now increasing.
  • The objective of this study was to evaluate and compare the clinicopathologic findings of gastric cardia and more distal stomach adenocarcinoma.
  • STUDY DESIGN: Patients included in our study were those who underwent operations for gastric adenocarcinoma in our institute from 1981 to 2006, and who had undergone complete medical history, including history of daily alcohol consumption; smoking; body mass index; and pathologic examinations.
  • A total of 843 patients were included in our study, and were divided into cardia and noncardia cancer groups.
  • RESULTS: Among the 843 patients, 23 (2.8%) had gastric cardia cancer.
  • Mean size of cardia tumors was larger than noncardia tumors.
  • Although noncardia cancer was often detected at an early stage, gastric cardia cancer was most often diagnosed at an advanced stage.
  • Pathologically, cardia cancer was more invasive and had more lymphatic permeation and lymph node metastasis than noncardia cancer.
  • CONCLUSIONS: Gastric cardia cancer occurs at a low incidence of only 2.8% of resected gastric cancers.
  • Unlike cases of gastric cardia cancer in Western populations, body mass index is not associated with occurrence of gastric cardia cancer in our study.
  • Because gastric cardia cancer appears more aggressive than noncardia gastric cancer, early diagnosis and intervention are important.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222384.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Früh M, Ruhstaller T, Neuweiler J, Cerny T: Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie; 2005 Jan;28(1):38-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation.
  • BACKGROUND: Skin metastases from gastric cancer are rare and generally occur at a very late stage in the course of the disease.
  • CASE REPORT: A 60-year-old patient with localized adenocarcinoma of the cardia (stage II) was primarily treated with extended total gastrectomy with transhiatal resection of the distal esophagus.
  • CONCLUSION: We report a long-term disease-free survival of a patient with isolated cutaneous metastases of a gastric cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Skin Neoplasms / secondary. Skin Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604627.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT: Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol; 2009 Nov 21;15(43):5465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection.
  • RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups.
  • CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Carcinoma, Squamous Cell / microbiology. Cardia / microbiology. Esophageal Neoplasms / microbiology. Helicobacter Infections / blood. Helicobacter Infections / complications. Helicobacter pylori / immunology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2008 Oct;38(10):760-5 [18837801.001]
  • [Cites] Gut. 2008 Jun;57(6):727-33 [17895354.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):658-60 [11531247.001]
  • [Cites] J Gastroenterol. 2002;37 Suppl 13:28-33 [12109662.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):68-76 [12559187.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):123-8 [12593607.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):129-34 [12593608.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1202-4 [14520446.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;212:13-8 [8578226.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1442-7 [9136820.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1316-21 [9260797.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1271-6 [9707050.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):621-4 [10428200.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):588-93 [15743356.001]
  • [Cites] Helicobacter. 2005 Aug;10(4):312-7 [16104947.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1999-2000 [16708392.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2827-31 [17036331.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1188-99 [17383866.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):933-40 [17613922.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • (PMID = 19916178.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2778104
  •  go-up   go-down


97. Whitson BA, Groth SS, Li Z, Kratzke RA, Maddaus MA: Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg; 2010 Jan;139(1):43-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas.
  • OBJECTIVE: Distal esophageal tumors and gastric cardia tumors, although only physically separated by centimeters, have different staging systems and are usually treated differently.
  • We hypothesized that gastroesophageal junction adenocarcinomas (eg, gastric cardia and distal esophageal tumors) were not distinct entities and had similar survival.
  • METHODS: Using the Surveillance, Epidemiology, and End Results database (1988-2005), we identified patients with adenocarcinomas of the distal esophagus (n = 1474) and gastric cardia (n = 192).
  • RESULTS: Even after adjusting for potential confounding covariates (location, stage, race, cancer-directed surgery, and radiation therapy), we found no significant difference between distal esophageal and gastric cardia tumors with regard to overall (hazard ratio, 1.18; 95% confidence interval, 0.99-1.41) and cancer-specific (hazard ratio, 1.09; 95% confidence interval, 0.90-1.31) survival.
  • CONCLUSION: Through a large, population-based analysis of gastric cardia and distal esophageal adenocarcinomas, we found that patients with gastroesophageal junction adenocarcinomas have similar survival rates.
  • Adenocarcinomas of the gastroesophageal junction are not distinct entities delineated by anatomic boundaries and as such should be managed by one skilled in both esophageal and gastric resections.
  • [MeSH-major] Cardia. Esophageal Neoplasms / mortality. Esophagogastric Junction. Stomach Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 19660401.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Ohdaira H, Noro T, Terada H, Kameyama J, Ohara T, Yoshino K, Kitajima M, Suzuki Y: New double-stapling technique for esophagojejunostomy and esophagogastrostomy in gastric cancer surgery, using a peroral intraluminal approach with a digital stapling system. Gastric Cancer; 2009;12(2):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New double-stapling technique for esophagojejunostomy and esophagogastrostomy in gastric cancer surgery, using a peroral intraluminal approach with a digital stapling system.
  • In the abdominal-transhiatal approach for resection of adenocarcinoma of the cardia or subcardia, and in laparoscopy-assisted total gastrectomy (LATG), the use of a circular stapling device has potential problems with the placement of the purse-string suture and insertion of the anvil of the instrument.
  • [MeSH-major] Digestive System Surgical Procedures / instrumentation. Digestive System Surgical Procedures / methods. Stomach Neoplasms / surgery. Surgical Stapling / instrumentation. Surgical Stapling / methods
  • [MeSH-minor] Anastomosis, Surgical / instrumentation. Anastomosis, Surgical / methods. Esophagus / surgery. Humans. Stomach / surgery. Surgical Staplers. Sutures

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2001;4(2):98-102 [11706768.001]
  • [Cites] Surg Clin North Am. 1989 Dec;69(6):1227-36 [2512659.001]
  • [Cites] Gastric Cancer. 2007;10(3):176-80 [17922096.001]
  • [Cites] Surg Technol Int. 2005;14:113-7 [16525962.001]
  • [Cites] Obes Surg. 2003 Dec;13(6):837-41 [14738666.001]
  • [Cites] Gastric Cancer. 2007;10(3):181-6 [17922097.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):50-2 [2405935.001]
  • [Cites] Gastric Cancer. 1999 Dec;2(4):230-234 [11957104.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):127-9 [9354169.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Aug;14(4):230-3 [15472555.001]
  • [Cites] Am J Surg. 2002 Jul;184(1):58-60 [12135722.001]
  • [Cites] Am J Surg. 1997 Jul;174(1):61-2 [9240954.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):174-6 [11574091.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1166-74 [16055298.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):909-12 [2804585.001]
  • [Cites] Obes Surg. 2003 Feb;13(1):88-94 [12630620.001]
  • (PMID = 19562464.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Kim MA, Lee HS, Yang HK, Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer; 2005 Apr 1;103(7):1439-46